#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Habenular	_
1-2	10-13	and	_
1-3	14-22	striatal	_
1-4	23-31	activity	_
1-5	32-38	during	_
1-6	39-50	performance	_
1-7	51-59	feedback	_
1-8	60-63	are	_
1-9	64-78	differentially	_
1-10	79-85	linked	_
1-11	86-90	with	_
1-12	91-101	state-like	_
1-13	102-105	and	_
1-14	106-116	trait-like	_
1-15	117-124	aspects	_
1-16	125-127	of	_
1-17	128-135	tobacco	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
1-18	136-139	use	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
1-19	140-148	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
1-20	149-151	We	_
1-21	152-162	dissociate	_
1-22	163-168	brain	_
1-23	169-176	changes	_
1-24	177-183	linked	_
1-25	184-186	to	_
1-26	187-195	nicotine	_
1-27	196-206	withdrawal	_
1-28	207-209	in	_
1-29	210-213	the	_
1-30	214-222	habenula	_
1-31	223-227	from	_
1-32	228-233	those	_
1-33	234-240	linked	_
1-34	241-243	to	_
1-35	244-253	addiction	_
1-36	254-262	severity	_
1-37	263-265	in	_
1-38	266-274	striatum	_
1-39	275-276	.	_

2-1	277-280	The	_
2-2	281-289	habenula	_
2-3	290-291	,	_
2-4	292-294	an	_
2-5	295-306	epithalamic	_
2-6	307-314	nucleus	_
2-7	315-323	involved	_
2-8	324-326	in	_
2-9	327-333	reward	_
2-10	334-337	and	_
2-11	338-346	aversive	_
2-12	347-357	processing	_
2-13	358-359	,	_
2-14	360-363	may	_
2-15	364-374	contribute	_
2-16	375-377	to	_
2-17	378-386	negative	_
2-18	387-400	reinforcement	_
2-19	401-411	mechanisms	_
2-20	412-423	maintaining	_
2-21	424-432	nicotine	_
2-22	433-436	use	_
2-23	437-438	.	_

3-1	439-441	We	_
3-2	442-446	used	_
3-3	447-448	a	_
3-4	449-460	performance	_
3-5	461-469	feedback	_
3-6	470-474	task	_
3-7	475-479	that	_
3-8	480-494	differentially	_
3-9	495-504	activates	_
3-10	505-508	the	_
3-11	509-517	striatum	_
3-12	518-521	and	_
3-13	522-530	habenula	_
3-14	531-534	and	_
3-15	535-547	administered	_
3-16	548-556	nicotine	_
3-17	557-560	and	_
3-18	561-572	varenicline	_
3-19	573-574	(	_
3-20	575-581	versus	_
3-21	582-590	placebos	_
3-22	591-592	)	_
3-23	593-595	to	_
3-24	596-615	overnight-abstinent	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
3-25	616-623	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
3-26	624-627	and	_
3-27	628-638	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
3-28	639-641	to	_
3-29	642-651	delineate	_
3-30	652-668	feedback-related	_
3-31	669-679	functional	_
3-32	680-685	brain	_
3-33	686-697	alterations	_
3-34	698-702	both	_
3-35	703-705	as	_
3-36	706-707	a	_
3-37	708-716	function	_
3-38	717-719	of	_
3-39	720-727	smoking	_
3-40	728-733	trait	_
3-41	734-735	(	_
3-42	736-743	smokers	_
3-43	744-750	versus	_
3-44	751-761	nonsmokers	_
3-45	762-763	)	_
3-46	764-767	and	_
3-47	768-772	drug	_
3-48	773-787	administration	_
3-49	788-793	state	_
3-50	794-795	(	_
3-51	796-800	drug	_
3-52	801-807	versus	_
3-53	808-815	placebo	_
3-54	816-817	)	_
3-55	818-819	.	_

4-1	820-827	Smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
4-2	828-834	showed	_
4-3	835-839	less	_
4-4	840-848	striatal	_
4-5	849-861	responsivity	_
4-6	862-864	to	_
4-7	865-873	positive	_
4-8	874-882	feedback	_
4-9	883-884	,	_
4-10	885-887	an	_
4-11	888-898	alteration	_
4-12	899-902	not	_
4-13	903-912	mitigated	_
4-14	913-915	by	_
4-15	916-920	drug	_
4-16	921-935	administration	_
4-17	936-937	,	_
4-18	938-941	but	_
4-19	942-948	rather	_
4-20	949-959	correlated	_
4-21	960-964	with	_
4-22	965-976	trait-level	_
4-23	977-986	addiction	_
4-24	987-995	severity	_
4-25	996-997	.	_

5-1	998-1008	Conversely	_
5-2	1009-1010	,	_
5-3	1011-1019	nicotine	_
5-4	1020-1034	administration	_
5-5	1035-1042	reduced	_
5-6	1043-1051	habenula	_
5-7	1052-1060	activity	_
5-8	1061-1070	following	_
5-9	1071-1075	both	_
5-10	1076-1084	positive	_
5-11	1085-1088	and	_
5-12	1089-1097	negative	_
5-13	1098-1106	feedback	_
5-14	1107-1112	among	_
5-15	1113-1122	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
5-16	1123-1130	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
5-17	1131-1132	,	_
5-18	1133-1136	but	_
5-19	1137-1140	not	_
5-20	1141-1151	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
5-21	1152-1153	,	_
5-22	1154-1157	and	_
5-23	1158-1167	increased	_
5-24	1168-1176	habenula	_
5-25	1177-1185	activity	_
5-26	1186-1191	among	_
5-27	1192-1199	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
5-28	1200-1210	correlated	_
5-29	1211-1215	with	_
5-30	1216-1224	elevated	_
5-31	1225-1236	state-level	_
5-32	1237-1244	tobacco	_
5-33	1245-1253	cravings	_
5-34	1254-1255	.	_

6-1	1256-1261	These	_
6-2	1262-1270	outcomes	_
6-3	1271-1280	highlight	_
6-4	1281-1282	a	_
6-5	1283-1295	dissociation	_
6-6	1296-1303	between	_
6-7	1304-1319	neurobiological	_
6-8	1320-1329	processes	_
6-9	1330-1336	linked	_
6-10	1337-1341	with	_
6-11	1342-1345	the	_
6-12	1346-1356	dependence	_
6-13	1357-1365	severity	_
6-14	1366-1371	trait	_
6-15	1372-1375	and	_
6-16	1376-1379	the	_
6-17	1380-1388	nicotine	_
6-18	1389-1399	withdrawal	_
6-19	1400-1405	state	_
6-20	1406-1407	.	_

7-1	1408-1421	Interventions	_
7-2	1422-1436	simultaneously	_
7-3	1437-1446	targeting	_
7-4	1447-1451	both	_
7-5	1452-1459	aspects	_
7-6	1460-1463	may	_
7-7	1464-1471	improve	_
7-8	1472-1481	currently	_
7-9	1482-1486	poor	_
7-10	1487-1496	cessation	_
7-11	1497-1505	outcomes	_
7-12	1506-1507	.	_

8-1	1508-1517	MATERIALS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-2	1518-1521	AND	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-3	1522-1529	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-4	1530-1542	Participants	_
8-5	1543-1544	A	_
8-6	1545-1550	total	_
8-7	1551-1553	of	_
8-8	1554-1556	24	_
8-9	1557-1577	nontreatment-seeking	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale
8-10	1578-1583	daily	_
8-11	1584-1593	cigarette	http://maven.renci.org/NeuroBridge/neurobridge#RSoftwareTool
8-12	1594-1601	smokers	http://maven.renci.org/NeuroBridge/neurobridge#RSoftwareTool
8-13	1602-1603	(	_
8-14	1604-1607	≥10	_
8-15	1608-1622	cigarettes/day	_
8-16	1623-1626	for	_
8-17	1627-1628	>	_
8-18	1629-1630	2	_
8-19	1631-1636	years	_
8-20	1637-1638	,	_
8-21	1639-1641	12	_
8-22	1642-1649	females	_
8-23	1650-1651	)	_
8-24	1652-1655	and	_
8-25	1656-1658	20	_
8-26	1659-1669	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
8-27	1670-1671	(	_
8-28	1672-1674	no	_
8-29	1675-1682	smoking	_
8-30	1683-1689	within	_
8-31	1690-1693	the	_
8-32	1694-1698	last	_
8-33	1699-1700	2	_
8-34	1701-1706	years	_
8-35	1707-1710	and	_
8-36	1711-1713	no	_
8-37	1714-1722	lifetime	_
8-38	1723-1730	history	_
8-39	1731-1733	of	_
8-40	1734-1739	daily	_
8-41	1740-1747	smoking	_
8-42	1748-1749	,	_
8-43	1750-1752	10	_
8-44	1753-1760	females	_
8-45	1761-1762	)	_
8-46	1763-1772	completed	_
8-47	1773-1776	the	_
8-48	1777-1782	study	_
8-49	1783-1784	.	_

9-1	1785-1788	All	_
9-2	1789-1791	44	_
9-3	1792-1804	participants	_
9-4	1805-1809	were	_
9-5	1810-1822	right-handed	_
9-6	1823-1824	,	_
9-7	1825-1829	were	_
9-8	1830-1832	18	_
9-9	1833-1835	to	_
9-10	1836-1838	55	_
9-11	1839-1844	years	_
9-12	1845-1847	of	_
9-13	1848-1851	age	_
9-14	1852-1853	,	_
9-15	1854-1857	and	_
9-16	1858-1862	were	_
9-17	1863-1872	recruited	_
9-18	1873-1875	at	_
9-19	1876-1879	the	_
9-20	1880-1888	National	_
9-21	1889-1898	Institute	_
9-22	1899-1901	on	_
9-23	1902-1906	Drug	_
9-24	1907-1923	Abuse–Intramural	_
9-25	1924-1932	Research	_
9-26	1933-1940	Program	_
9-27	1941-1942	(	_
9-28	1943-1951	NIDA-IRP	_
9-29	1952-1953	)	_
9-30	1954-1956	in	_
9-31	1957-1966	Baltimore	_
9-32	1967-1968	,	_
9-33	1969-1971	MD	_
9-34	1972-1973	.	_

10-1	1974-1986	Participants	_
10-2	1987-1991	were	_
10-3	1992-1999	healthy	_
10-4	2000-2004	with	_
10-5	2005-2007	no	_
10-6	2008-2016	reported	_
10-7	2017-2024	history	_
10-8	2025-2027	of	_
10-9	2028-2032	drug	_
10-10	2033-2043	dependence	_
10-11	2044-2045	(	_
10-12	2046-2051	other	_
10-13	2052-2056	than	_
10-14	2057-2065	nicotine	_
10-15	2066-2068	in	_
10-16	2069-2076	smokers	_
10-17	2077-2078	)	_
10-18	2079-2080	,	_
10-19	2081-2093	neurological	_
10-20	2094-2096	or	_
10-21	2097-2108	psychiatric	_
10-22	2109-2118	disorders	_
10-23	2119-2120	,	_
10-24	2121-2135	cardiovascular	_
10-25	2136-2138	or	_
10-26	2139-2144	renal	_
10-27	2145-2156	impairments	_
10-28	2157-2158	,	_
10-29	2159-2167	diabetes	_
10-30	2168-2169	,	_
10-31	2170-2172	or	_
10-32	2173-2176	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
10-33	2177-2194	contraindications	_
10-34	2195-2196	.	_

11-1	2197-2206	Cigarette	_
11-2	2207-2214	smokers	_
11-3	2215-2219	were	_
11-4	2220-2222	36	_
11-5	2223-2224	±	_
11-6	2225-2227	10	_
11-7	2228-2233	years	_
11-8	2234-2237	old	_
11-9	2238-2239	(	_
11-10	2240-2244	mean	_
11-11	2245-2246	±	_
11-12	2247-2249	SD	_
11-13	2250-2251	)	_
11-14	2252-2253	,	_
11-15	2254-2262	reported	_
11-16	2263-2268	daily	_
11-17	2269-2276	smoking	_
11-18	2277-2280	for	_
11-19	2281-2283	18	_
11-20	2284-2285	±	_
11-21	2286-2288	11	_
11-22	2289-2294	years	_
11-23	2295-2296	,	_
11-24	2297-2303	smoked	_
11-25	2304-2306	18	_
11-26	2307-2308	±	_
11-27	2309-2310	8	_
11-28	2311-2325	cigarettes/day	_
11-29	2326-2327	,	_
11-30	2328-2331	and	_
11-31	2332-2336	were	_
11-32	2337-2347	moderately	_
11-33	2348-2356	nicotine	_
11-34	2357-2366	dependent	_
11-35	2367-2368	(	_
11-36	2369-2373	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
11-37	2374-2380	scores	_
11-38	2381-2382	:	_
11-39	2383-2384	5	_
11-40	2385-2386	±	_
11-41	2387-2388	2	_
11-42	2389-2390	;	_
11-43	2391-2396	table	_
11-44	2397-2399	S1	_
11-45	2400-2401	)	_
11-46	2402-2403	.	_

12-1	2404-2406	As	_
12-2	2407-2417	nonsmokers	_
12-3	2418-2422	were	_
12-4	2423-2430	younger	_
12-5	2431-2432	(	_
12-6	2433-2435	30	_
12-7	2436-2437	±	_
12-8	2438-2439	7	_
12-9	2440-2445	years	_
12-10	2446-2449	old	_
12-11	2450-2451	)	_
12-12	2452-2456	than	_
12-13	2457-2464	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
12-14	2465-2466	,	_
12-15	2467-2469	we	_
12-16	2470-2480	considered	_
12-17	2481-2484	the	_
12-18	2485-2494	influence	_
12-19	2495-2497	of	_
12-20	2498-2501	age	_
12-21	2502-2506	when	_
12-22	2507-2516	comparing	_
12-23	2517-2523	groups	_
12-24	2524-2525	.	_

13-1	2526-2529	The	_
13-2	2530-2537	results	_
13-3	2538-2541	and	_
13-4	2542-2557	interpretations	_
13-5	2558-2562	when	_
13-6	2563-2572	including	_
13-7	2573-2576	age	_
13-8	2577-2579	as	_
13-9	2580-2581	a	_
13-10	2582-2591	covariate	_
13-11	2592-2594	in	_
13-12	2595-2608	between-group	_
13-13	2609-2619	behavioral	_
13-14	2620-2623	and	_
13-15	2624-2636	neuroimaging	_
13-16	2637-2648	assessments	_
13-17	2649-2653	were	_
13-18	2654-2657	the	_
13-19	2658-2662	same	_
13-20	2663-2665	as	_
13-21	2666-2670	when	_
13-22	2671-2674	age	_
13-23	2675-2678	was	_
13-24	2679-2682	not	_
13-25	2683-2691	included	_
13-26	2692-2693	.	_

14-1	2694-2697	All	_
14-2	2698-2710	participants	_
14-3	2711-2712	’	_
14-4	2713-2717	data	_
14-5	2718-2722	were	_
14-6	2723-2727	used	_
14-7	2728-2730	in	_
14-8	2731-2741	behavioral	_
14-9	2742-2753	assessments	_
14-10	2754-2755	;	_
14-11	2756-2763	however	_
14-12	2764-2765	,	_
14-13	2766-2769	for	_
14-14	2770-2777	imaging	_
14-15	2778-2789	assessments	_
14-16	2790-2791	,	_
14-17	2792-2796	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
14-18	2797-2801	data	_
14-19	2802-2806	from	_
14-20	2807-2810	two	_
14-21	2811-2815	male	_
14-22	2816-2823	smokers	_
14-23	2824-2827	and	_
14-24	2828-2831	one	_
14-25	2832-2836	male	_
14-26	2837-2846	nonsmoker	_
14-27	2847-2851	were	_
14-28	2852-2860	excluded	_
14-29	2861-2868	because	_
14-30	2869-2871	of	_
14-31	2872-2881	excessive	_
14-32	2882-2886	head	_
14-33	2887-2893	motion	_
14-34	2894-2900	during	_
14-35	2901-2909	scanning	_
14-36	2910-2911	(	_
14-37	2912-2920	criteria	_
14-38	2921-2930	described	_
14-39	2931-2936	below	_
14-40	2937-2938	)	_
14-41	2939-2940	.	_

15-1	2941-2943	We	_
15-2	2944-2952	obtained	_
15-3	2953-2960	written	_
15-4	2961-2969	informed	_
15-5	2970-2977	consent	_
15-6	2978-2980	in	_
15-7	2981-2991	accordance	_
15-8	2992-2996	with	_
15-9	2997-3000	the	_
15-10	3001-3009	NIDA-IRP	_
15-11	3010-3023	Institutional	_
15-12	3024-3030	Review	_
15-13	3031-3036	Board	_
15-14	3037-3038	,	_
15-15	3039-3042	and	_
15-16	3043-3053	volunteers	_
15-17	3054-3058	were	_
15-18	3059-3070	compensated	_
15-19	3071-3074	for	_
15-20	3075-3088	participation	_
15-21	3089-3090	.	_

16-1	3091-3095	This	_
16-2	3096-3101	study	_
16-3	3102-3105	was	_
16-4	3106-3116	registered	_
16-5	3117-3119	at	_
16-6	3120-3138	clinicaltrials.gov	_
16-7	3139-3140	(	_
16-8	3141-3152	NCT00830739	_
16-9	3153-3154	)	_
16-10	3155-3156	.	_

17-1	3157-3169	Experimental	_
17-2	3170-3176	design	_
17-3	3177-3180	and	_
17-4	3181-3191	procedures	_
17-5	3192-3194	We	_
17-6	3195-3204	collected	_
17-7	3205-3216	self-report	_
17-8	3217-3230	questionnaire	_
17-9	3231-3232	,	_
17-10	3233-3243	behavioral	_
17-11	3244-3248	task	_
17-12	3249-3260	performance	_
17-13	3261-3262	,	_
17-14	3263-3266	and	_
17-15	3267-3270	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
17-16	3271-3275	data	_
17-17	3276-3280	from	_
17-18	3281-3293	participants	_
17-19	3294-3296	in	_
17-20	3297-3300	the	_
17-21	3301-3308	context	_
17-22	3309-3311	of	_
17-23	3312-3313	a	_
17-24	3314-3332	within-participant	_
17-25	3333-3334	,	_
17-26	3335-3347	double-blind	_
17-27	3348-3349	,	_
17-28	3350-3368	placebo-controlled	_
17-29	3369-3370	,	_
17-30	3371-3380	crossover	_
17-31	3381-3386	study	_
17-32	3387-3388	,	_
17-33	3389-3398	involving	_
17-34	3399-3402	two	_
17-35	3403-3408	drugs	_
17-36	3409-3410	:	_
17-37	3411-3422	transdermal	_
17-38	3423-3431	nicotine	_
17-39	3432-3433	(	_
17-40	3434-3442	NicoDerm	_
17-41	3443-3445	CQ	_
17-42	3446-3447	,	_
17-43	3448-3463	GlaxoSmithKline	_
17-44	3464-3465	)	_
17-45	3466-3469	and	_
17-46	3470-3474	oral	_
17-47	3475-3486	varenicline	_
17-48	3487-3488	(	_
17-49	3489-3496	Chantix	_
17-50	3497-3498	,	_
17-51	3499-3505	Pfizer	_
17-52	3506-3507	)	_
17-53	3508-3509	.	_

18-1	3510-3513	The	_
18-2	3514-3516	6-	_
18-3	3517-3519	to	_
18-4	3520-3526	8-week	_
18-5	3527-3532	study	_
18-6	3533-3541	duration	_
18-7	3542-3550	involved	_
18-8	3551-3552	a	_
18-9	3553-3558	total	_
18-10	3559-3561	of	_
18-11	3562-3566	nine	_
18-12	3567-3573	visits	_
18-13	3574-3575	,	_
18-14	3576-3580	each	_
18-15	3581-3583	on	_
18-16	3584-3593	different	_
18-17	3594-3598	days	_
18-18	3599-3600	(	_
18-19	3601-3604	one	_
18-20	3605-3616	orientation	_
18-21	3617-3618	,	_
18-22	3619-3622	two	_
18-23	3623-3637	neurocognitive	_
18-24	3638-3639	,	_
18-25	3640-3643	and	_
18-26	3644-3647	six	_
18-27	3648-3660	neuroimaging	_
18-28	3661-3667	visits	_
18-29	3668-3669	;	_
18-30	3670-3673	Fig	_
18-31	3674-3675	.	_

19-1	3676-3678	1A	_
19-2	3679-3680	)	_
19-3	3681-3682	.	_

20-1	3683-3689	During	_
20-2	3690-3693	the	_
20-3	3694-3705	orientation	_
20-4	3706-3711	visit	_
20-5	3712-3713	,	_
20-6	3714-3726	participants	_
20-7	3727-3731	gave	_
20-8	3732-3740	informed	_
20-9	3741-3748	consent	_
20-10	3749-3750	,	_
20-11	3751-3760	completed	_
20-12	3761-3769	baseline	_
20-13	3770-3781	self-report	_
20-14	3782-3790	measures	_
20-15	3791-3792	,	_
20-16	3793-3796	and	_
20-17	3797-3805	received	_
20-18	3806-3814	training	_
20-19	3815-3817	on	_
20-20	3818-3826	multiple	_
20-21	3827-3839	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
20-22	3840-3845	tasks	_
20-23	3846-3847	(	_
20-24	3848-3851	one	_
20-25	3852-3861	described	_
20-26	3862-3868	herein	_
20-27	3869-3870	)	_
20-28	3871-3872	.	_

21-1	3873-3877	Task	_
21-2	3878-3890	instructions	_
21-3	3891-3895	were	_
21-4	3896-3905	initially	_
21-5	3906-3915	explained	_
21-6	3916-3918	at	_
21-7	3919-3920	a	_
21-8	3921-3926	bench	_
21-9	3927-3935	computer	_
21-10	3936-3937	,	_
21-11	3938-3941	and	_
21-12	3942-3946	then	_
21-13	3947-3955	practice	_
21-14	3956-3959	was	_
21-15	3960-3969	completed	_
21-16	3970-3972	in	_
21-17	3973-3974	a	_
21-18	3975-3979	mock	_
21-19	3980-3983	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
21-20	3984-3991	scanner	_
21-21	3992-3993	.	_

22-1	3994-4000	During	_
22-2	4001-4004	the	_
22-3	4005-4019	neurocognitive	_
22-4	4020-4026	visits	_
22-5	4027-4028	,	_
22-6	4029-4041	participants	_
22-7	4042-4051	completed	_
22-8	4052-4063	self-report	_
22-9	4064-4072	measures	_
22-10	4073-4076	and	_
22-11	4077-4087	behavioral	_
22-12	4088-4095	testing	_
22-13	4096-4097	(	_
22-14	4098-4101	not	_
22-15	4102-4111	described	_
22-16	4112-4119	further	_
22-17	4120-4121	)	_
22-18	4122-4123	.	_

23-1	4124-4126	At	_
23-2	4127-4132	three	_
23-3	4133-4137	time	_
23-4	4138-4144	points	_
23-5	4145-4151	during	_
23-6	4152-4153	a	_
23-7	4154-4165	varenicline	_
23-8	4166-4180	administration	_
23-9	4181-4188	regimen	_
23-10	4189-4190	[	_
23-11	4191-4195	PILL	_
23-12	4196-4202	factor	_
23-13	4203-4204	:	_
23-14	4205-4213	pre-pill	_
23-15	4214-4215	(	_
23-16	4216-4224	baseline	_
23-17	4225-4226	)	_
23-18	4227-4233	versus	_
23-19	4234-4241	placebo	_
23-20	4242-4248	versus	_
23-21	4249-4260	varenicline	_
23-22	4261-4262	]	_
23-23	4263-4264	,	_
23-24	4265-4277	participants	_
23-25	4278-4287	completed	_
23-26	4288-4291	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-27	4292-4300	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-28	4301-4303	on	_
23-29	4304-4307	two	_
23-30	4308-4317	occasions	_
23-31	4318-4319	,	_
23-32	4320-4324	once	_
23-33	4325-4330	while	_
23-34	4331-4338	wearing	_
23-35	4339-4340	a	_
23-36	4341-4349	nicotine	_
23-37	4350-4355	patch	_
23-38	4356-4359	and	_
23-39	4360-4364	once	_
23-40	4365-4370	while	_
23-41	4371-4378	wearing	_
23-42	4379-4380	a	_
23-43	4381-4388	placebo	_
23-44	4389-4394	patch	_
23-45	4395-4396	(	_
23-46	4397-4402	PATCH	_
23-47	4403-4409	factor	_
23-48	4410-4411	)	_
23-49	4412-4413	.	_

24-1	4414-4423	Following	_
24-2	4424-4427	two	_
24-3	4428-4435	initial	_
24-4	4436-4444	pre-pill	_
24-5	4445-4452	imaging	_
24-6	4453-4461	sessions	_
24-7	4462-4463	,	_
24-8	4464-4468	each	_
24-9	4469-4480	participant	_
24-10	4481-4490	underwent	_
24-11	4491-4494	~17	_
24-12	4495-4499	days	_
24-13	4500-4502	of	_
24-14	4503-4514	varenicline	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalSymptom
24-15	4515-4518	and	_
24-16	4519-4526	placebo	_
24-17	4527-4531	pill	_
24-18	4532-4546	administration	_
24-19	4547-4550	and	_
24-20	4551-4560	completed	_
24-21	4561-4569	nicotine	_
24-22	4570-4573	and	_
24-23	4574-4581	placebo	_
24-24	4582-4587	patch	_
24-25	4588-4594	visits	_
24-26	4595-4601	toward	_
24-27	4602-4605	the	_
24-28	4606-4609	end	_
24-29	4610-4612	of	_
24-30	4613-4617	both	_
24-31	4618-4622	pill	_
24-32	4623-4630	periods	_
24-33	4631-4632	.	_

25-1	4633-4639	During	_
25-2	4640-4644	each	_
25-3	4645-4647	of	_
25-4	4648-4651	the	_
25-5	4652-4655	six	_
25-6	4656-4668	neuroimaging	_
25-7	4669-4673	days	_
25-8	4674-4675	,	_
25-9	4676-4688	participants	_
25-10	4689-4698	completed	_
25-11	4699-4702	two	_
25-12	4703-4706	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-13	4707-4715	sessions	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-14	4716-4723	lasting	_
25-15	4724-4726	~2	_
25-16	4727-4732	hours	_
25-17	4733-4737	each	_
25-18	4738-4739	(	_
25-19	4740-4742	an	_
25-20	4743-4747	a.m.	_
25-21	4748-4751	and	_
25-22	4752-4753	a	_
25-23	4754-4758	p.m.	_
25-24	4759-4766	session	_
25-25	4767-4768	)	_
25-26	4769-4770	.	_

26-1	4771-4774	The	_
26-2	4775-4779	a.m.	_
26-3	4780-4787	session	_
26-4	4788-4793	began	_
26-5	4794-4796	~2	_
26-6	4797-4799	to	_
26-7	4800-4803	2.5	_
26-8	4804-4809	hours	_
26-9	4810-4815	after	_
26-10	4816-4821	patch	_
26-11	4822-4833	application	_
26-12	4834-4835	.	_

27-1	4836-4842	During	_
27-2	4843-4847	this	_
27-3	4848-4855	session	_
27-4	4856-4857	,	_
27-5	4858-4870	participants	_
27-6	4871-4880	completed	_
27-7	4881-4882	a	_
27-8	4883-4890	Flanker	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-9	4891-4895	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-10	4896-4897	,	_
27-11	4898-4899	a	_
27-12	4900-4911	performance	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
27-13	4912-4920	feedback	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
27-14	4921-4925	task	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
27-15	4926-4927	(	_
27-16	4928-4937	described	_
27-17	4938-4943	below	_
27-18	4944-4945	)	_
27-19	4946-4947	,	_
27-20	4948-4951	and	_
27-21	4952-4953	a	_
27-22	4954-4962	response	_
27-23	4963-4973	inhibition	_
27-24	4974-4978	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-25	4979-4980	.	_

28-1	4981-4984	The	_
28-2	4985-4996	performance	_
28-3	4997-5005	feedback	_
28-4	5006-5010	task	_
28-5	5011-5014	was	_
28-6	5015-5024	completed	_
28-7	5025-5028	~45	_
28-8	5029-5032	min	_
28-9	5033-5038	after	_
28-10	5039-5046	scanner	_
28-11	5047-5052	entry	_
28-12	5053-5056	and	_
28-13	5057-5060	2.5	_
28-14	5061-5063	to	_
28-15	5064-5067	3.5	_
28-16	5068-5073	hours	_
28-17	5074-5079	after	_
28-18	5080-5085	patch	_
28-19	5086-5097	application	_
28-20	5098-5099	.	_

29-1	5100-5111	Varenicline	_
29-2	5112-5115	was	_
29-3	5116-5128	administered	_
29-4	5129-5138	according	_
29-5	5139-5141	to	_
29-6	5142-5150	standard	_
29-7	5151-5161	guidelines	_
29-8	5162-5171	beginning	_
29-9	5172-5176	with	_
29-10	5177-5178	a	_
29-11	5179-5189	once-daily	_
29-12	5190-5194	dose	_
29-13	5195-5197	of	_
29-14	5198-5201	0.5	_
29-15	5202-5204	mg	_
29-16	5205-5207	on	_
29-17	5208-5212	days	_
29-18	5213-5214	1	_
29-19	5215-5217	to	_
29-20	5218-5219	3	_
29-21	5220-5221	,	_
29-22	5222-5225	0.5	_
29-23	5226-5228	mg	_
29-24	5229-5234	twice	_
29-25	5235-5240	daily	_
29-26	5241-5243	on	_
29-27	5244-5248	days	_
29-28	5249-5250	4	_
29-29	5251-5253	to	_
29-30	5254-5255	7	_
29-31	5256-5257	,	_
29-32	5258-5261	and	_
29-33	5262-5271	increased	_
29-34	5272-5274	to	_
29-35	5275-5276	1	_
29-36	5277-5279	mg	_
29-37	5280-5285	twice	_
29-38	5286-5291	daily	_
29-39	5292-5294	on	_
29-40	5295-5299	days	_
29-41	5300-5301	8	_
29-42	5302-5304	to	_
29-43	5305-5307	17	_
29-44	5308-5309	.	_

30-1	5310-5311	(	_
30-2	5312-5358	www.pfizer.com/products/product-detail/chantix	_
30-3	5359-5360	)	_
30-4	5361-5362	.	_

31-1	5363-5369	Active	_
31-2	5370-5381	varenicline	_
31-3	5382-5385	and	_
31-4	5386-5393	placebo	_
31-5	5394-5399	pills	_
31-6	5400-5404	were	_
31-7	5405-5413	packaged	_
31-8	5414-5416	to	_
31-9	5417-5419	be	_
31-10	5420-5429	identical	_
31-11	5430-5432	in	_
31-12	5433-5443	appearance	_
31-13	5444-5445	.	_

32-1	5446-5454	Scanning	_
32-2	5455-5463	sessions	_
32-3	5464-5472	occurred	_
32-4	5473-5475	at	_
32-5	5476-5479	the	_
32-6	5480-5483	end	_
32-7	5484-5486	of	_
32-8	5487-5491	each	_
32-9	5492-5499	regimen	_
32-10	5500-5501	(	_
32-11	5502-5513	varenicline	_
32-12	5514-5515	,	_
32-13	5516-5520	17.0	_
32-14	5521-5522	±	_
32-15	5523-5526	4.2	_
32-16	5527-5531	days	_
32-17	5532-5533	;	_
32-18	5534-5541	placebo	_
32-19	5542-5546	pill	_
32-20	5547-5548	,	_
32-21	5549-5553	16.5	_
32-22	5554-5555	±	_
32-23	5556-5559	3.4	_
32-24	5560-5564	days	_
32-25	5565-5566	)	_
32-26	5567-5568	.	_

33-1	5569-5573	Pill	_
33-2	5574-5588	administration	_
33-3	5589-5596	periods	_
33-4	5597-5601	were	_
33-5	5602-5605	not	_
33-6	5606-5615	separated	_
33-7	5616-5618	by	_
33-8	5619-5620	a	_
33-9	5621-5628	washout	_
33-10	5629-5637	interval	_
33-11	5638-5639	.	_

34-1	5640-5643	For	_
34-2	5644-5656	participants	_
34-3	5657-5661	with	_
34-4	5662-5663	a	_
34-5	5664-5671	placebo	_
34-6	5672-5679	regimen	_
34-7	5680-5684	that	_
34-8	5685-5693	followed	_
34-9	5694-5697	the	_
34-10	5698-5709	varenicline	_
34-11	5710-5717	regimen	_
34-12	5718-5719	,	_
34-13	5720-5729	carryover	_
34-14	5730-5737	effects	_
34-15	5738-5742	were	_
34-16	5743-5750	assumed	_
34-17	5751-5761	negligible	_
34-18	5762-5767	given	_
34-19	5768-5771	the	_
34-20	5772-5780	~24-hour	_
34-21	5781-5792	elimination	_
34-22	5793-5802	half-life	_
34-23	5803-5805	of	_
34-24	5806-5817	varenicline	_
34-25	5818-5821	and	_
34-26	5822-5825	the	_
34-27	5826-5830	fact	_
34-28	5831-5835	that	_
34-29	5836-5843	placebo	_
34-30	5844-5848	pill	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
34-31	5849-5857	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
34-32	5858-5866	sessions	_
34-33	5867-5870	and	_
34-34	5871-5877	active	_
34-35	5878-5889	varenicline	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
34-36	5890-5894	pill	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
34-37	5895-5903	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
34-38	5904-5912	sessions	_
34-39	5913-5917	were	_
34-40	5918-5927	separated	_
34-41	5928-5930	by	_
34-42	5931-5935	more	_
34-43	5936-5940	than	_
34-44	5941-5942	2	_
34-45	5943-5948	weeks	_
34-46	5949-5950	.	_

35-1	5951-5960	Adherence	_
35-2	5961-5963	to	_
35-3	5964-5967	the	_
35-4	5968-5972	pill	_
35-5	5973-5980	regimen	_
35-6	5981-5984	was	_
35-7	5985-5994	confirmed	_
35-8	5995-5997	by	_
35-9	5998-6002	pill	_
35-10	6003-6008	count	_
35-11	6009-6012	and	_
35-12	6013-6024	participant	_
35-13	6025-6036	self-report	_
35-14	6037-6040	the	_
35-15	6041-6048	morning	_
35-16	6049-6051	of	_
35-17	6052-6056	each	_
35-18	6057-6060	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
35-19	6061-6066	visit	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
35-20	6067-6068	;	_
35-21	6069-6073	data	_
35-22	6074-6076	on	_
35-23	6077-6087	medication	_
35-24	6088-6097	adherence	_
35-25	6098-6102	have	_
35-26	6103-6107	been	_
35-27	6108-6116	reported	_
35-28	6117-6126	elsewhere	_
35-29	6127-6128	.	_

36-1	6129-6133	Pill	_
36-2	6134-6141	regimen	_
36-3	6142-6146	side	_
36-4	6147-6154	effects	_
36-5	6155-6158	and	_
36-6	6159-6168	adherence	_
36-7	6169-6173	were	_
36-8	6174-6183	monitored	_
36-9	6184-6186	by	_
36-10	6187-6194	regular	_
36-11	6195-6204	telephone	_
36-12	6205-6216	assessments	_
36-13	6217-6220	and	_
36-14	6221-6223	at	_
36-15	6224-6233	in-person	_
36-16	6234-6240	visits	_
36-17	6241-6242	.	_

37-1	6243-6246	For	_
37-2	6247-6251	each	_
37-3	6252-6254	of	_
37-4	6255-6258	the	_
37-5	6259-6263	pill	_
37-6	6264-6274	conditions	_
37-7	6275-6276	,	_
37-8	6277-6285	nicotine	_
37-9	6286-6288	or	_
37-10	6289-6296	placebo	_
37-11	6297-6304	patches	_
37-12	6305-6309	were	_
37-13	6310-6317	applied	_
37-14	6318-6320	to	_
37-15	6321-6324	the	_
37-16	6325-6330	upper	_
37-17	6331-6335	back	_
37-18	6336-6338	at	_
37-19	6339-6342	the	_
37-20	6343-6348	start	_
37-21	6349-6351	of	_
37-22	6352-6356	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
37-23	6357-6363	visits	_
37-24	6364-6365	(	_
37-25	6366-6375	separated	_
37-26	6376-6378	by	_
37-27	6379-6382	2.9	_
37-28	6383-6384	±	_
37-29	6385-6388	1.7	_
37-30	6389-6393	days	_
37-31	6394-6395	)	_
37-32	6396-6397	.	_

38-1	6398-6401	The	_
38-2	6402-6407	patch	_
38-3	6408-6411	was	_
38-4	6412-6416	worn	_
38-5	6417-6420	for	_
38-6	6421-6424	the	_
38-7	6425-6433	duration	_
38-8	6434-6436	of	_
38-9	6437-6441	each	_
38-10	6442-6448	9-hour	_
38-11	6449-6461	neuroimaging	_
38-12	6462-6467	visit	_
38-13	6468-6469	.	_

39-1	6470-6485	Pharmacokinetic	_
39-2	6486-6490	data	_
39-3	6491-6499	indicate	_
39-4	6500-6504	that	_
39-5	6505-6511	plasma	_
39-6	6512-6520	nicotine	_
39-7	6521-6535	concentrations	_
39-8	6536-6541	reach	_
39-9	6542-6543	a	_
39-10	6544-6548	peak	_
39-11	6549-6555	within	_
39-12	6556-6557	2	_
39-13	6558-6560	to	_
39-14	6561-6562	4	_
39-15	6563-6568	hours	_
39-16	6569-6574	after	_
39-17	6575-6580	patch	_
39-18	6581-6592	application	_
39-19	6593-6594	,	_
39-20	6595-6601	remain	_
39-21	6602-6612	relatively	_
39-22	6613-6619	stable	_
39-23	6620-6623	for	_
39-24	6624-6627	the	_
39-25	6628-6632	next	_
39-26	6633-6634	4	_
39-27	6635-6637	to	_
39-28	6638-6639	6	_
39-29	6640-6645	hours	_
39-30	6646-6647	,	_
39-31	6648-6651	and	_
39-32	6652-6656	then	_
39-33	6657-6666	gradually	_
39-34	6667-6675	decrease	_
39-35	6676-6685	beginning	_
39-36	6686-6688	~8	_
39-37	6689-6691	to	_
39-38	6692-6694	10	_
39-39	6695-6700	hours	_
39-40	6701-6706	after	_
39-41	6707-6718	application	_
39-42	6719-6720	.	_

40-1	6721-6726	Hence	_
40-2	6727-6728	,	_
40-3	6729-6733	data	_
40-4	6734-6744	collection	_
40-5	6745-6753	occurred	_
40-6	6754-6760	within	_
40-7	6761-6762	a	_
40-8	6763-6765	2-	_
40-9	6766-6768	to	_
40-10	6769-6775	9-hour	_
40-11	6776-6785	postpatch	_
40-12	6786-6792	window	_
40-13	6793-6803	associated	_
40-14	6804-6808	with	_
40-15	6809-6815	steady	_
40-16	6816-6822	plasma	_
40-17	6823-6831	nicotine	_
40-18	6832-6838	levels	_
40-19	6839-6840	.	_

41-1	6841-6844	All	_
41-2	6845-6855	nonsmokers	_
41-3	6856-6860	were	_
41-4	6861-6873	administered	_
41-5	6874-6878	7-mg	_
41-6	6879-6887	nicotine	_
41-7	6888-6895	patches	_
41-8	6896-6897	.	_

42-1	6898-6901	For	_
42-2	6902-6909	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
42-3	6910-6911	,	_
42-4	6912-6913	a	_
42-5	6914-6922	multiple	_
42-6	6923-6929	dosing	_
42-7	6930-6938	strategy	_
42-8	6939-6942	was	_
42-9	6943-6947	used	_
42-10	6948-6950	to	_
42-11	6951-6956	match	_
42-12	6957-6962	daily	_
42-13	6963-6971	nicotine	_
42-14	6972-6978	intake	_
42-15	6979-6980	:	_
42-16	6981-6983	21	_
42-17	6984-6986	mg	_
42-18	6987-6988	(	_
42-19	6989-6991	10	_
42-20	6992-6994	to	_
42-21	6995-6997	15	_
42-22	6998-7012	cigarettes/day	_
42-23	7013-7014	;	_
42-24	7015-7016	n	_
42-25	7017-7018	=	_
42-26	7019-7021	11	_
42-27	7022-7023	)	_
42-28	7024-7025	,	_
42-29	7026-7028	28	_
42-30	7029-7031	mg	_
42-31	7032-7033	(	_
42-32	7034-7036	16	_
42-33	7037-7039	to	_
42-34	7040-7042	20	_
42-35	7043-7057	cigarettes/day	_
42-36	7058-7059	;	_
42-37	7060-7061	n	_
42-38	7062-7063	=	_
42-39	7064-7065	9	_
42-40	7066-7067	)	_
42-41	7068-7069	,	_
42-42	7070-7072	35	_
42-43	7073-7075	mg	_
42-44	7076-7077	(	_
42-45	7078-7080	21	_
42-46	7081-7083	to	_
42-47	7084-7086	25	_
42-48	7087-7101	cigarettes/day	_
42-49	7102-7103	;	_
42-50	7104-7105	n	_
42-51	7106-7107	=	_
42-52	7108-7109	1	_
42-53	7110-7111	)	_
42-54	7112-7113	,	_
42-55	7114-7117	and	_
42-56	7118-7120	42	_
42-57	7121-7123	mg	_
42-58	7124-7125	(	_
42-59	7126-7127	>	_
42-60	7128-7130	25	_
42-61	7131-7145	cigarettes/day	_
42-62	7146-7147	;	_
42-63	7148-7149	n	_
42-64	7150-7151	=	_
42-65	7152-7153	3	_
42-66	7154-7155	)	_
42-67	7156-7157	.	_

43-1	7158-7167	Overnight	_
43-2	7168-7178	abstinence	_
43-3	7179-7182	was	_
43-4	7183-7191	required	_
43-5	7192-7194	on	_
43-6	7195-7207	neuroimaging	_
43-7	7208-7212	days	_
43-8	7213-7214	.	_

44-1	7215-7222	Smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
44-2	7223-7227	were	_
44-3	7228-7238	instructed	_
44-4	7239-7241	to	_
44-5	7242-7246	have	_
44-6	7247-7252	their	_
44-7	7253-7257	last	_
44-8	7258-7267	cigarette	_
44-9	7268-7270	12	_
44-10	7271-7276	hours	_
44-11	7277-7283	before	_
44-12	7284-7289	their	_
44-13	7290-7299	scheduled	_
44-14	7300-7307	arrival	_
44-15	7308-7309	.	_

45-1	7310-7313	All	_
45-2	7314-7326	participants	_
45-3	7327-7331	were	_
45-4	7332-7342	instructed	_
45-5	7343-7345	to	_
45-6	7346-7353	abstain	_
45-7	7354-7358	from	_
45-8	7359-7366	alcohol	_
45-9	7367-7370	for	_
45-10	7371-7373	24	_
45-11	7374-7379	hours	_
45-12	7380-7383	and	_
45-13	7384-7386	to	_
45-14	7387-7395	moderate	_
45-15	7396-7404	caffeine	_
45-16	7405-7411	intake	_
45-17	7412-7415	for	_
45-18	7416-7418	12	_
45-19	7419-7424	hours	_
45-20	7425-7426	.	_

46-1	7427-7431	Upon	_
46-2	7432-7439	arrival	_
46-3	7440-7441	,	_
46-4	7442-7445	all	_
46-5	7446-7458	participants	_
46-6	7459-7463	were	_
46-7	7464-7470	tested	_
46-8	7471-7474	for	_
46-9	7475-7481	recent	_
46-10	7482-7486	drug	_
46-11	7487-7490	and	_
46-12	7491-7498	alcohol	_
46-13	7499-7502	use	_
46-14	7503-7506	and	_
46-15	7507-7510	for	_
46-16	7511-7518	expired	_
46-17	7519-7525	carbon	_
46-18	7526-7534	monoxide	_
46-19	7535-7536	(	_
46-20	7537-7539	CO	_
46-21	7540-7541	)	_
46-22	7542-7548	levels	_
46-23	7549-7550	.	_

47-1	7551-7552	A	_
47-2	7553-7555	CO	_
47-3	7556-7565	guideline	_
47-4	7566-7568	of	_
47-5	7569-7573	less	_
47-6	7574-7578	than	_
47-7	7579-7581	15	_
47-8	7582-7587	parts	_
47-9	7588-7591	per	_
47-10	7592-7599	million	_
47-11	7600-7601	(	_
47-12	7602-7605	ppm	_
47-13	7606-7607	)	_
47-14	7608-7611	was	_
47-15	7612-7616	used	_
47-16	7617-7619	to	_
47-17	7620-7626	verify	_
47-18	7627-7634	smoking	_
47-19	7635-7645	abstinence	_
47-20	7646-7647	.	_

48-1	7648-7658	Indicative	_
48-2	7659-7661	of	_
48-3	7662-7672	compliance	_
48-4	7673-7674	,	_
48-5	7675-7682	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
48-6	7683-7684	’	_
48-7	7685-7687	CO	_
48-8	7688-7694	levels	_
48-9	7695-7699	were	_
48-10	7700-7705	lower	_
48-11	7706-7708	at	_
48-12	7709-7721	neuroimaging	_
48-13	7722-7728	visits	_
48-14	7729-7730	(	_
48-15	7731-7734	7.1	_
48-16	7735-7736	±	_
48-17	7737-7740	2.6	_
48-18	7741-7744	ppm	_
48-19	7745-7746	)	_
48-20	7747-7749	in	_
48-21	7750-7760	comparison	_
48-22	7761-7763	to	_
48-23	7764-7767	the	_
48-24	7768-7779	orientation	_
48-25	7780-7783	and	_
48-26	7784-7798	neurocognitive	_
48-27	7799-7805	visits	_
48-28	7806-7810	that	_
48-29	7811-7814	did	_
48-30	7815-7818	not	_
48-31	7819-7826	require	_
48-32	7827-7837	abstinence	_
48-33	7838-7839	[	_
48-34	7840-7844	18.9	_
48-35	7845-7846	±	_
48-36	7847-7850	8.9	_
48-37	7851-7854	ppm	_
48-38	7855-7856	;	_
48-39	7857-7858	t	_
48-40	7859-7860	(	_
48-41	7861-7863	23	_
48-42	7864-7865	)	_
48-43	7866-7867	=	_
48-44	7868-7872	−8.2	_
48-45	7873-7874	,	_
48-46	7875-7876	P	_
48-47	7877-7878	<	_
48-48	7879-7884	0.001	_
48-49	7885-7886	]	_
48-50	7887-7888	.	_

49-1	7889-7899	Nonsmokers	_
49-2	7900-7901	’	_
49-3	7902-7904	CO	_
49-4	7905-7911	levels	_
49-5	7912-7915	did	_
49-6	7916-7919	not	_
49-7	7920-7926	differ	_
49-8	7927-7934	between	_
49-9	7935-7940	these	_
49-10	7941-7947	visits	_
49-11	7948-7949	(	_
49-12	7950-7960	abstinence	_
49-13	7961-7969	required	_
49-14	7970-7971	,	_
49-15	7972-7975	1.9	_
49-16	7976-7977	±	_
49-17	7978-7981	0.3	_
49-18	7982-7985	ppm	_
49-19	7986-7987	;	_
49-20	7988-7991	not	_
49-21	7992-8000	required	_
49-22	8001-8002	,	_
49-23	8003-8006	1.8	_
49-24	8007-8008	±	_
49-25	8009-8012	0.4	_
49-26	8013-8016	ppm	_
49-27	8017-8018	;	_
49-28	8019-8020	P	_
49-29	8021-8022	=	_
49-30	8023-8026	0.2	_
49-31	8027-8028	)	_
49-32	8029-8030	.	_

50-1	8031-8042	Self-report	_
50-2	8043-8051	measures	_
50-3	8052-8054	We	_
50-4	8055-8063	assessed	_
50-5	8064-8074	clinically	_
50-6	8075-8083	relevant	_
50-7	8084-8094	constructs	_
50-8	8095-8096	(	_
50-9	8097-8106	addiction	_
50-10	8107-8115	severity	_
50-11	8116-8117	,	_
50-12	8118-8125	tobacco	_
50-13	8126-8133	craving	_
50-14	8134-8135	,	_
50-15	8136-8142	affect	_
50-16	8143-8144	,	_
50-17	8145-8148	and	_
50-18	8149-8158	anhedonia	_
50-19	8159-8160	)	_
50-20	8161-8166	using	_
50-21	8167-8177	previously	_
50-22	8178-8187	validated	_
50-23	8188-8191	and	_
50-24	8192-8200	commonly	_
50-25	8201-8205	used	_
50-26	8206-8217	self-report	_
50-27	8218-8229	instruments	_
50-28	8230-8231	.	_

51-1	8232-8234	In	_
51-2	8235-8238	the	_
51-3	8239-8246	context	_
51-4	8247-8249	of	_
51-5	8250-8259	cigarette	_
51-6	8260-8267	smoking	_
51-7	8268-8269	,	_
51-8	8270-8279	addiction	_
51-9	8280-8288	severity	_
51-10	8289-8291	is	_
51-11	8292-8301	typically	_
51-12	8302-8312	quantified	_
51-13	8313-8317	with	_
51-14	8318-8321	the	_
51-15	8322-8330	six-item	_
51-16	8331-8335	FTND	_
51-17	8336-8337	.	_

52-1	8338-8342	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
52-2	8343-8349	scores	_
52-3	8350-8353	are	_
52-4	8354-8360	highly	_
52-5	8361-8370	heritable	_
52-6	8371-8374	and	_
52-7	8375-8384	routinely	_
52-8	8385-8389	used	_
52-9	8390-8392	as	_
52-10	8393-8394	a	_
52-11	8395-8402	primary	_
52-12	8403-8412	phenotype	_
52-13	8413-8415	in	_
52-14	8416-8423	studies	_
52-15	8424-8431	linking	_
52-16	8432-8439	smoking	_
52-17	8440-8449	behaviors	_
52-18	8450-8454	with	_
52-19	8455-8460	nAChR	_
52-20	8461-8464	and	_
52-21	8465-8470	other	_
52-22	8471-8478	genetic	_
52-23	8479-8487	variants	_
52-24	8488-8489	.	_

53-1	8490-8495	Hence	_
53-2	8496-8497	,	_
53-3	8498-8500	we	_
53-4	8501-8515	conceptualized	_
53-5	8516-8520	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
53-6	8521-8527	scores	_
53-7	8528-8529	(	_
53-8	8530-8535	range	_
53-9	8536-8537	,	_
53-10	8538-8539	1	_
53-11	8540-8542	to	_
53-12	8543-8545	10	_
53-13	8546-8547	)	_
53-14	8548-8557	collected	_
53-15	8558-8564	during	_
53-16	8565-8568	the	_
53-17	8569-8580	orientation	_
53-18	8581-8586	visit	_
53-19	8587-8589	as	_
53-20	8590-8591	a	_
53-21	8592-8603	trait-level	_
53-22	8604-8611	measure	_
53-23	8612-8614	of	_
53-24	8615-8623	nicotine	_
53-25	8624-8633	addiction	_
53-26	8634-8642	severity	_
53-27	8643-8644	.	_

54-1	8645-8657	Additionally	_
54-2	8658-8659	,	_
54-3	8660-8666	smoker	_
54-4	8667-8668	’	_
54-5	8669-8670	s	_
54-6	8671-8678	tobacco	_
54-7	8679-8687	cravings	_
54-8	8688-8692	were	_
54-9	8693-8701	assessed	_
54-10	8702-8706	each	_
54-11	8707-8719	neuroimaging	_
54-12	8720-8725	visit	_
54-13	8726-8730	with	_
54-14	8731-8734	the	_
54-15	8735-8742	12-item	_
54-16	8743-8744	,	_
54-17	8745-8750	short	_
54-18	8751-8755	form	_
54-19	8756-8758	of	_
54-20	8759-8762	the	_
54-21	8763-8766	TCQ	_
54-22	8767-8768	.	_

55-1	8769-8772	TCQ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
55-2	8773-8778	items	_
55-3	8779-8783	were	_
55-4	8784-8789	rated	_
55-5	8790-8792	on	_
55-6	8793-8794	a	_
55-7	8795-8806	seven-point	_
55-8	8807-8812	scale	_
55-9	8813-8814	(	_
55-10	8815-8823	strongly	_
55-11	8824-8832	disagree	_
55-12	8833-8835	to	_
55-13	8836-8844	strongly	_
55-14	8845-8850	agree	_
55-15	8851-8852	)	_
55-16	8853-8856	and	_
55-17	8857-8864	yielded	_
55-18	8865-8866	a	_
55-19	8867-8872	total	_
55-20	8873-8878	score	_
55-21	8879-8880	(	_
55-22	8881-8886	range	_
55-23	8887-8888	,	_
55-24	8889-8891	12	_
55-25	8892-8894	to	_
55-26	8895-8897	84	_
55-27	8898-8899	)	_
55-28	8900-8903	and	_
55-29	8904-8908	four	_
55-30	8909-8917	subscale	_
55-31	8918-8924	scores	_
55-32	8925-8926	(	_
55-33	8927-8939	emotionality	_
55-34	8940-8941	,	_
55-35	8942-8952	expectancy	_
55-36	8953-8954	,	_
55-37	8955-8967	compulsivity	_
55-38	8968-8969	,	_
55-39	8970-8973	and	_
55-40	8974-8988	purposefulness	_
55-41	8989-8990	)	_
55-42	8991-8992	.	_

56-1	8993-8995	We	_
56-2	8996-9003	focused	_
56-3	9004-9006	on	_
56-4	9007-9010	the	_
56-5	9011-9014	TCQ	_
56-6	9015-9020	total	_
56-7	9021-9026	score	_
56-8	9027-9031	that	_
56-9	9032-9034	we	_
56-10	9035-9049	conceptualized	_
56-11	9050-9052	as	_
56-12	9053-9054	a	_
56-13	9055-9066	state-level	_
56-14	9067-9074	measure	_
56-15	9075-9077	of	_
56-16	9078-9086	nicotine	_
56-17	9087-9097	withdrawal	_
56-18	9098-9104	status	_
56-19	9105-9106	.	_

57-1	9107-9110	All	_
57-2	9111-9123	participants	_
57-3	9124-9128	also	_
57-4	9129-9138	completed	_
57-5	9139-9150	instruments	_
57-6	9151-9153	to	_
57-7	9154-9160	assess	_
57-8	9161-9167	affect	_
57-9	9168-9171	and	_
57-10	9172-9181	anhedonia	_
57-11	9182-9184	at	_
57-12	9185-9189	each	_
57-13	9190-9202	neuroimaging	_
57-14	9203-9208	visit	_
57-15	9209-9210	.	_

58-1	9211-9223	Specifically	_
58-2	9224-9225	,	_
58-3	9226-9238	participants	_
58-4	9239-9248	completed	_
58-5	9249-9252	the	_
58-6	9253-9258	PANAS	http://maven.renci.org/NeuroBridge/neurobridge#Analyzer
58-7	9259-9260	,	_
58-8	9261-9266	which	_
58-9	9267-9269	is	_
58-10	9270-9278	composed	_
58-11	9279-9281	of	_
58-12	9282-9285	two	_
58-13	9286-9293	10-item	_
58-14	9294-9300	scales	_
58-15	9301-9310	assessing	_
58-16	9311-9319	positive	_
58-17	9320-9326	affect	_
58-18	9327-9328	(	_
58-19	9329-9335	active	_
58-20	9336-9337	,	_
58-21	9338-9343	alert	_
58-22	9344-9345	,	_
58-23	9346-9355	attentive	_
58-24	9356-9357	,	_
58-25	9358-9368	determined	_
58-26	9369-9370	,	_
58-27	9371-9383	enthusiastic	_
58-28	9384-9385	,	_
58-29	9386-9393	excited	_
58-30	9394-9395	,	_
58-31	9396-9404	inspired	_
58-32	9405-9406	,	_
58-33	9407-9417	interested	_
58-34	9418-9419	,	_
58-35	9420-9425	proud	_
58-36	9426-9427	,	_
58-37	9428-9431	and	_
58-38	9432-9438	strong	_
58-39	9439-9440	)	_
58-40	9441-9444	and	_
58-41	9445-9453	negative	_
58-42	9454-9460	affect	_
58-43	9461-9462	(	_
58-44	9463-9469	afraid	_
58-45	9470-9471	,	_
58-46	9472-9479	ashamed	_
58-47	9480-9481	,	_
58-48	9482-9492	distressed	_
58-49	9493-9494	,	_
58-50	9495-9501	guilty	_
58-51	9502-9503	,	_
58-52	9504-9511	hostile	_
58-53	9512-9513	,	_
58-54	9514-9523	irritable	_
58-55	9524-9525	,	_
58-56	9526-9533	jittery	_
58-57	9534-9535	,	_
58-58	9536-9543	nervous	_
58-59	9544-9545	,	_
58-60	9546-9552	scared	_
58-61	9553-9554	,	_
58-62	9555-9558	and	_
58-63	9559-9564	upset	_
58-64	9565-9566	)	_
58-65	9567-9568	.	_

59-1	9569-9574	PANAS	http://maven.renci.org/NeuroBridge/neurobridge#Analyzer
59-2	9575-9580	items	_
59-3	9581-9585	were	_
59-4	9586-9591	rated	_
59-5	9592-9594	on	_
59-6	9595-9596	a	_
59-7	9597-9607	five-point	_
59-8	9608-9613	scale	_
59-9	9614-9615	(	_
59-10	9616-9619	not	_
59-11	9620-9622	at	_
59-12	9623-9631	all/very	_
59-13	9632-9638	little	_
59-14	9639-9641	to	_
59-15	9642-9651	extremely	_
59-16	9652-9653	)	_
59-17	9654-9662	yielding	_
59-18	9663-9671	positive	_
59-19	9672-9675	and	_
59-20	9676-9684	negative	_
59-21	9685-9691	affect	_
59-22	9692-9698	scores	_
59-23	9699-9703	with	_
59-24	9704-9705	a	_
59-25	9706-9714	possible	_
59-26	9715-9720	range	_
59-27	9721-9725	from	_
59-28	9726-9728	10	_
59-29	9729-9731	to	_
59-30	9732-9734	50	_
59-31	9735-9736	.	_

60-1	9737-9749	Participants	_
60-2	9750-9754	also	_
60-3	9755-9764	completed	_
60-4	9765-9768	the	_
60-5	9769-9773	RSAS	_
60-6	9774-9775	,	_
60-7	9776-9781	which	_
60-8	9782-9784	is	_
60-9	9785-9786	a	_
60-10	9787-9794	40-item	_
60-11	9795-9805	true-false	_
60-12	9806-9819	questionnaire	_
60-13	9820-9824	that	_
60-14	9825-9833	measures	_
60-15	9834-9842	pleasure	_
60-16	9843-9844	(	_
60-17	9845-9847	or	_
60-18	9848-9852	lack	_
60-19	9853-9860	thereof	_
60-20	9861-9862	)	_
60-21	9863-9870	derived	_
60-22	9871-9875	from	_
60-23	9876-9889	interpersonal	_
60-24	9890-9897	sources	_
60-25	9898-9899	.	_

61-1	9900-9904	RSAS	_
61-2	9905-9910	items	_
61-3	9911-9914	are	_
61-4	9915-9928	dichotomously	_
61-5	9929-9935	scored	_
61-6	9936-9937	,	_
61-7	9938-9941	and	_
61-8	9942-9947	total	_
61-9	9948-9954	scores	_
61-10	9955-9960	range	_
61-11	9961-9965	from	_
61-12	9966-9967	0	_
61-13	9968-9970	to	_
61-14	9971-9973	40	_
61-15	9974-9978	such	_
61-16	9979-9983	that	_
61-17	9984-9990	higher	_
61-18	9991-9997	values	_
61-19	9998-10006	indicate	_
61-20	10007-10014	greater	_
61-21	10015-10021	levels	_
61-22	10022-10024	of	_
61-23	10025-10034	anhedonia	_
61-24	10035-10036	.	_

62-1	10037-10045	Elevated	_
62-2	10046-10052	social	_
62-3	10053-10062	anhedonia	_
62-4	10063-10065	is	_
62-5	10066-10072	common	_
62-6	10073-10078	among	_
62-7	10079-10090	individuals	_
62-8	10091-10100	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
62-9	10101-10105	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
62-10	10106-10116	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
62-11	10117-10120	and	_
62-12	10121-10134	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
62-13	10135-10136	,	_
62-14	10137-10140	two	_
62-15	10141-10157	neuropsychiatric	_
62-16	10158-10168	conditions	_
62-17	10169-10175	linked	_
62-18	10176-10180	with	_
62-19	10181-10189	aberrant	_
62-20	10190-10198	habenula	_
62-21	10199-10207	function	_
62-22	10208-10211	and	_
62-23	10212-10214	in	_
62-24	10215-10220	which	_
62-25	10221-10228	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
62-26	10229-10232	are	_
62-27	10233-10248	overrepresented	_
62-28	10249-10250	.	_

63-1	10251-10254	The	_
63-2	10255-10258	TCQ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
63-3	10259-10260	(	_
63-4	10261-10268	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
63-5	10269-10273	only	_
63-6	10274-10275	)	_
63-7	10276-10277	,	_
63-8	10278-10283	PANAS	http://maven.renci.org/NeuroBridge/neurobridge#Analyzer
63-9	10284-10285	,	_
63-10	10286-10289	and	_
63-11	10290-10294	RSAS	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
63-12	10295-10299	were	_
63-13	10300-10309	collected	_
63-14	10310-10314	each	_
63-15	10315-10327	neuroimaging	_
63-16	10328-10333	visit	_
63-17	10334-10338	~1.5	_
63-18	10339-10344	hours	_
63-19	10345-10350	after	_
63-20	10351-10361	completion	_
63-21	10362-10364	of	_
63-22	10365-10368	the	_
63-23	10369-10380	performance	_
63-24	10381-10389	feedback	_
63-25	10390-10394	task	_
63-26	10395-10396	.	_

64-1	10397-10408	Performance	_
64-2	10409-10417	feedback	_
64-3	10418-10422	task	_
64-4	10423-10425	At	_
64-5	10426-10430	each	_
64-6	10431-10443	neuroimaging	_
64-7	10444-10449	visit	_
64-8	10450-10451	,	_
64-9	10452-10464	participants	_
64-10	10465-10474	performed	_
64-11	10475-10476	a	_
64-12	10477-10485	positive	_
64-13	10486-10489	and	_
64-14	10490-10498	negative	_
64-15	10499-10510	performance	_
64-16	10511-10519	feedback	_
64-17	10520-10524	task	_
64-18	10525-10526	,	_
64-19	10527-10533	called	_
64-20	10534-10537	the	_
64-21	10538-10544	motion	_
64-22	10545-10555	prediction	_
64-23	10556-10560	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
64-24	10561-10562	,	_
64-25	10563-10573	previously	_
64-26	10574-10579	shown	_
64-27	10580-10582	to	_
64-28	10583-10597	differentially	_
64-29	10598-10606	activate	_
64-30	10607-10610	the	_
64-31	10611-10619	habenula	_
64-32	10620-10621	,	_
64-33	10622-10625	ACC	_
64-34	10626-10627	,	_
64-35	10628-10634	insula	_
64-36	10635-10636	,	_
64-37	10637-10640	and	_
64-38	10641-10648	ventral	_
64-39	10649-10657	striatum	_
64-40	10658-10659	.	_

65-1	10660-10663	The	_
65-2	10664-10676	participants	_
65-3	10677-10678	’	_
65-4	10679-10688	objective	_
65-5	10689-10692	was	_
65-6	10693-10695	to	_
65-7	10696-10703	predict	_
65-8	10704-10709	which	_
65-9	10710-10712	of	_
65-10	10713-10716	two	_
65-11	10717-10723	moving	_
65-12	10724-10729	balls	_
65-13	10730-10731	,	_
65-14	10732-10740	starting	_
65-15	10741-10745	from	_
65-16	10746-10755	different	_
65-17	10756-10765	locations	_
65-18	10766-10769	and	_
65-19	10770-10779	traveling	_
65-20	10780-10782	at	_
65-21	10783-10792	different	_
65-22	10793-10799	speeds	_
65-23	10800-10801	,	_
65-24	10802-10807	would	_
65-25	10808-10810	be	_
65-26	10811-10814	the	_
65-27	10815-10820	first	_
65-28	10821-10823	to	_
65-29	10824-10829	reach	_
65-30	10830-10831	a	_
65-31	10832-10838	finish	_
65-32	10839-10843	line	_
65-33	10844-10849	after	_
65-34	10850-10857	viewing	_
65-35	10858-10859	a	_
65-36	10860-10865	brief	_
65-37	10866-10870	clip	_
65-38	10871-10873	of	_
65-39	10874-10877	the	_
65-40	10878-10883	balls	_
65-41	10884-10885	’	_
65-42	10886-10892	motion	_
65-43	10893-10894	(	_
65-44	10895-10898	Fig	_
65-45	10899-10900	.	_

66-1	10901-10903	1B	_
66-2	10904-10905	)	_
66-3	10906-10907	.	_

67-1	10908-10912	Each	_
67-2	10913-10918	trial	_
67-3	10919-10924	began	_
67-4	10925-10929	with	_
67-5	10930-10931	a	_
67-6	10932-10940	variable	_
67-7	10941-10949	fixation	_
67-8	10950-10958	interval	_
67-9	10959-10960	(	_
67-10	10961-10965	3500	_
67-11	10966-10968	to	_
67-12	10969-10973	4500	_
67-13	10974-10976	ms	_
67-14	10977-10978	)	_
67-15	10979-10980	,	_
67-16	10981-10986	which	_
67-17	10987-10990	was	_
67-18	10991-10999	followed	_
67-19	11000-11002	by	_
67-20	11003-11006	the	_
67-21	11007-11017	appearance	_
67-22	11018-11020	of	_
67-23	11021-11024	the	_
67-24	11025-11031	finish	_
67-25	11032-11036	line	_
67-26	11037-11038	(	_
67-27	11039-11042	500	_
67-28	11043-11045	ms	_
67-29	11046-11047	)	_
67-30	11048-11050	to	_
67-31	11051-11058	signify	_
67-32	11059-11061	an	_
67-33	11062-11070	upcoming	_
67-34	11071-11077	motion	_
67-35	11078-11083	event	_
67-36	11084-11085	.	_

68-1	11086-11098	Participants	_
68-2	11099-11103	then	_
68-3	11104-11110	viewed	_
68-4	11111-11112	a	_
68-5	11113-11118	short	_
68-6	11119-11127	sequence	_
68-7	11128-11129	(	_
68-8	11130-11134	1400	_
68-9	11135-11137	ms	_
68-10	11138-11139	)	_
68-11	11140-11142	of	_
68-12	11143-11146	the	_
68-13	11147-11150	two	_
68-14	11151-11156	balls	_
68-15	11157-11166	traveling	_
68-16	11167-11169	at	_
68-17	11170-11179	different	_
68-18	11180-11186	speeds	_
68-19	11187-11191	from	_
68-20	11192-11201	different	_
68-21	11202-11210	starting	_
68-22	11211-11220	locations	_
68-23	11221-11223	on	_
68-24	11224-11227	the	_
68-25	11228-11232	left	_
68-26	11233-11237	side	_
68-27	11238-11240	of	_
68-28	11241-11244	the	_
68-29	11245-11251	screen	_
68-30	11252-11258	toward	_
68-31	11259-11262	the	_
68-32	11263-11269	finish	_
68-33	11270-11274	line	_
68-34	11275-11277	on	_
68-35	11278-11281	the	_
68-36	11282-11287	right	_
68-37	11288-11292	side	_
68-38	11293-11295	of	_
68-39	11296-11299	the	_
68-40	11300-11306	screen	_
68-41	11307-11308	.	_

69-1	11309-11314	Still	_
69-2	11315-11318	far	_
69-3	11319-11323	from	_
69-4	11324-11327	the	_
69-5	11328-11334	finish	_
69-6	11335-11339	line	_
69-7	11340-11341	,	_
69-8	11342-11345	the	_
69-9	11346-11351	balls	_
69-10	11352-11363	disappeared	_
69-11	11364-11365	,	_
69-12	11366-11369	and	_
69-13	11370-11373	the	_
69-14	11374-11382	question	_
69-15	11383-11384	“	_
69-16	11385-11390	Which	_
69-17	11391-11395	ball	_
69-18	11396-11397	?	_
69-19	11398-11399	”	_
69-20	11400-11403	was	_
69-21	11404-11413	presented	_
69-22	11414-11415	(	_
69-23	11416-11420	1350	_
69-24	11421-11423	ms	_
69-25	11424-11425	)	_
69-26	11426-11427	.	_

70-1	11428-11440	Participants	_
70-2	11441-11450	indicated	_
70-3	11451-11456	their	_
70-4	11457-11476	prediction/decision	_
70-5	11477-11480	via	_
70-6	11481-11482	a	_
70-7	11483-11495	right-handed	_
70-8	11496-11502	button	_
70-9	11503-11508	press	_
70-10	11509-11513	with	_
70-11	11514-11520	either	_
70-12	11521-11524	the	_
70-13	11525-11530	index	_
70-14	11531-11532	(	_
70-15	11533-11537	ball	_
70-16	11538-11539	1	_
70-17	11540-11541	)	_
70-18	11542-11544	or	_
70-19	11545-11551	middle	_
70-20	11552-11558	finger	_
70-21	11559-11560	(	_
70-22	11561-11565	ball	_
70-23	11566-11567	2	_
70-24	11568-11569	)	_
70-25	11570-11576	during	_
70-26	11577-11581	this	_
70-27	11582-11590	response	_
70-28	11591-11597	window	_
70-29	11598-11599	.	_

71-1	11600-11605	After	_
71-2	11606-11607	a	_
71-3	11608-11613	fixed	_
71-4	11614-11619	delay	_
71-5	11620-11621	(	_
71-6	11622-11625	750	_
71-7	11626-11628	ms	_
71-8	11629-11630	)	_
71-9	11631-11632	,	_
71-10	11633-11644	performance	_
71-11	11645-11653	feedback	_
71-12	11654-11655	(	_
71-13	11656-11662	emojis	_
71-14	11663-11664	)	_
71-15	11665-11670	about	_
71-16	11671-11674	the	_
71-17	11675-11686	correctness	_
71-18	11687-11689	of	_
71-19	11690-11693	the	_
71-20	11694-11706	participants	_
71-21	11707-11708	’	_
71-22	11709-11719	prediction	_
71-23	11720-11723	was	_
71-24	11724-11733	presented	_
71-25	11734-11735	(	_
71-26	11736-11740	1000	_
71-27	11741-11743	ms	_
71-28	11744-11745	)	_
71-29	11746-11747	.	_

72-1	11748-11759	Performance	_
72-2	11760-11768	feedback	_
72-3	11769-11772	was	_
72-4	11773-11782	delivered	_
72-5	11783-11785	to	_
72-6	11786-11798	participants	_
72-7	11799-11801	in	_
72-8	11802-11803	a	_
72-9	11804-11814	two-factor	_
72-10	11815-11816	,	_
72-11	11817-11825	FEEDBACK	_
72-12	11826-11827	[	_
72-13	11828-11839	informative	_
72-14	11840-11841	(	_
72-15	11842-11843	i	_
72-16	11844-11845	)	_
72-17	11846-11852	versus	_
72-18	11853-11867	noninformative	_
72-19	11868-11869	(	_
72-20	11870-11871	n	_
72-21	11872-11873	)	_
72-22	11874-11875	]	_
72-23	11876-11877	*	_
72-24	11878-11886	RESPONSE	_
72-25	11887-11888	[	_
72-26	11889-11896	correct	_
72-27	11897-11898	(	_
72-28	11899-11900	C	_
72-29	11901-11902	)	_
72-30	11903-11909	versus	_
72-31	11910-11915	error	_
72-32	11916-11917	(	_
72-33	11918-11919	E	_
72-34	11920-11921	)	_
72-35	11922-11923	]	_
72-36	11924-11925	,	_
72-37	11926-11933	fashion	_
72-38	11934-11935	.	_

73-1	11936-11941	Under	_
73-2	11942-11953	informative	_
73-3	11954-11962	feedback	_
73-4	11963-11964	,	_
73-5	11965-11977	participants	_
73-6	11978-11984	always	_
73-7	11985-11993	received	_
73-8	11994-12002	positive	_
73-9	12003-12011	feedback	_
73-10	12012-12013	(	_
73-11	12014-12018	i.e.	_
73-12	12019-12020	,	_
73-13	12021-12022	a	_
73-14	12023-12028	happy	_
73-15	12029-12034	emoji	_
73-16	12035-12036	)	_
73-17	12037-12046	following	_
73-18	12047-12048	a	_
73-19	12049-12056	correct	_
73-20	12057-12065	response	_
73-21	12066-12067	(	_
73-22	12068-12070	iC	_
73-23	12071-12072	)	_
73-24	12073-12076	and	_
73-25	12077-12083	always	_
73-26	12084-12092	received	_
73-27	12093-12101	negative	_
73-28	12102-12110	feedback	_
73-29	12111-12112	(	_
73-30	12113-12117	i.e.	_
73-31	12118-12119	,	_
73-32	12120-12121	a	_
73-33	12122-12125	sad	_
73-34	12126-12131	emoji	_
73-35	12132-12133	)	_
73-36	12134-12143	following	_
73-37	12144-12146	an	_
73-38	12147-12156	erroneous	_
73-39	12157-12165	response	_
73-40	12166-12167	(	_
73-41	12168-12170	iE	_
73-42	12171-12172	)	_
73-43	12173-12174	.	_

74-1	12175-12180	Under	_
74-2	12181-12195	noninformative	_
74-3	12196-12204	feedback	_
74-4	12205-12206	,	_
74-5	12207-12219	participants	_
74-6	12220-12228	received	_
74-7	12229-12231	no	_
74-8	12232-12243	information	_
74-9	12244-12246	on	_
74-10	12247-12254	whether	_
74-11	12255-12259	they	_
74-12	12260-12264	gave	_
74-13	12265-12266	a	_
74-14	12267-12274	correct	_
74-15	12275-12277	or	_
74-16	12278-12287	erroneous	_
74-17	12288-12296	response	_
74-18	12297-12299	as	_
74-19	12300-12303	the	_
74-20	12304-12308	same	_
74-21	12309-12317	feedback	_
74-22	12318-12321	was	_
74-23	12322-12331	presented	_
74-24	12332-12334	on	_
74-25	12335-12339	both	_
74-26	12340-12342	nC	_
74-27	12343-12346	and	_
74-28	12347-12349	nE	_
74-29	12350-12356	trials	_
74-30	12357-12358	(	_
74-31	12359-12363	i.e.	_
74-32	12364-12365	,	_
74-33	12366-12368	an	_
74-34	12369-12378	ambiguous	_
74-35	12379-12384	emoji	_
74-36	12385-12386	)	_
74-37	12387-12388	.	_

75-1	12389-12400	Informative	_
75-2	12401-12409	feedback	_
75-3	12410-12413	was	_
75-4	12414-12423	presented	_
75-5	12424-12426	on	_
75-6	12427-12429	73	_
75-7	12430-12431	%	_
75-8	12432-12434	of	_
75-9	12435-12441	trials	_
75-10	12442-12445	and	_
75-11	12446-12460	noninformative	_
75-12	12461-12469	feedback	_
75-13	12470-12472	on	_
75-14	12473-12475	27	_
75-15	12476-12477	%	_
75-16	12478-12479	.	_

76-1	12480-12484	This	_
76-2	12485-12493	feedback	_
76-3	12494-12502	schedule	_
76-4	12503-12510	allowed	_
76-5	12511-12513	us	_
76-6	12514-12516	to	_
76-7	12517-12526	determine	_
76-8	12527-12532	which	_
76-9	12533-12545	task-related	_
76-10	12546-12552	aspect	_
76-11	12553-12557	more	_
76-12	12558-12566	robustly	_
76-13	12567-12577	influenced	_
76-14	12578-12583	brain	_
76-15	12584-12592	activity	_
76-16	12593-12594	,	_
76-17	12595-12601	namely	_
76-18	12602-12603	,	_
76-19	12604-12607	the	_
76-20	12608-12612	type	_
76-21	12613-12615	of	_
76-22	12616-12624	feedback	_
76-23	12625-12626	(	_
76-24	12627-12635	positive	_
76-25	12636-12642	versus	_
76-26	12643-12651	negative	_
76-27	12652-12653	)	_
76-28	12654-12656	or	_
76-29	12657-12660	the	_
76-30	12661-12665	type	_
76-31	12666-12668	of	_
76-32	12669-12677	response	_
76-33	12678-12679	(	_
76-34	12680-12687	correct	_
76-35	12688-12694	versus	_
76-36	12695-12700	error	_
76-37	12701-12702	)	_
76-38	12703-12704	.	_

77-1	12705-12717	Task-related	_
77-2	12718-12722	BOLD	_
77-3	12723-12729	signal	_
77-4	12730-12736	change	_
77-5	12737-12740	was	_
77-6	12741-12752	anticipated	_
77-7	12753-12755	to	_
77-8	12756-12758	be	_
77-9	12759-12767	robustly	_
77-10	12768-12777	modulated	_
77-11	12778-12780	on	_
77-12	12781-12786	error	_
77-13	12787-12793	versus	_
77-14	12794-12801	correct	_
77-15	12802-12808	trials	_
77-16	12809-12813	when	_
77-17	12814-12822	followed	_
77-18	12823-12825	by	_
77-19	12826-12837	informative	_
77-20	12838-12846	feedback	_
77-21	12847-12848	.	_

78-1	12849-12851	If	_
78-2	12852-12864	participants	_
78-3	12865-12871	failed	_
78-4	12872-12874	to	_
78-5	12875-12882	respond	_
78-6	12883-12889	during	_
78-7	12890-12893	the	_
78-8	12894-12904	designated	_
78-9	12905-12913	response	_
78-10	12914-12920	window	_
78-11	12921-12922	,	_
78-12	12923-12927	then	_
78-13	12928-12932	they	_
78-14	12933-12941	received	_
78-15	12942-12943	a	_
78-16	12944-12949	fifth	_
78-17	12950-12954	type	_
78-18	12955-12957	of	_
78-19	12958-12966	feedback	_
78-20	12967-12968	(	_
78-21	12969-12973	i.e.	_
78-22	12974-12975	,	_
78-23	12976-12977	a	_
78-24	12978-12986	confused	_
78-25	12987-12992	emoji	_
78-26	12993-12994	)	_
78-27	12995-12998	for	_
78-28	12999-13004	these	_
78-29	13005-13016	no-response	_
78-30	13017-13023	trials	_
78-31	13024-13025	.	_

79-1	13026-13030	Task	_
79-2	13031-13041	difficulty	_
79-3	13042-13043	,	_
79-4	13044-13059	operationalized	_
79-5	13060-13062	as	_
79-6	13063-13066	the	_
79-7	13067-13071	time	_
79-8	13072-13082	difference	_
79-9	13083-13090	between	_
79-10	13091-13094	the	_
79-11	13095-13098	two	_
79-12	13099-13104	balls	_
79-13	13105-13106	’	_
79-14	13107-13114	arrival	_
79-15	13115-13117	at	_
79-16	13118-13121	the	_
79-17	13122-13128	finish	_
79-18	13129-13133	line	_
79-19	13134-13135	,	_
79-20	13136-13139	was	_
79-21	13140-13151	dynamically	_
79-22	13152-13163	manipulated	_
79-23	13164-13166	on	_
79-24	13167-13170	the	_
79-25	13171-13176	basis	_
79-26	13177-13179	of	_
79-27	13180-13184	each	_
79-28	13185-13196	participant	_
79-29	13197-13198	’	_
79-30	13199-13200	s	_
79-31	13201-13209	behavior	_
79-32	13210-13212	to	_
79-33	13213-13221	maintain	_
79-34	13222-13227	error	_
79-35	13228-13233	rates	_
79-36	13234-13236	at	_
79-37	13237-13240	~35	_
79-38	13241-13242	%	_
79-39	13243-13244	(	_
79-40	13245-13249	i.e.	_
79-41	13250-13251	,	_
79-42	13252-13254	an	_
79-43	13255-13260	error	_
79-44	13261-13265	rate	_
79-45	13266-13273	between	_
79-46	13274-13277	0.3	_
79-47	13278-13281	and	_
79-48	13282-13285	0.4	_
79-49	13286-13290	over	_
79-50	13291-13292	a	_
79-51	13293-13300	sliding	_
79-52	13301-13307	window	_
79-53	13308-13309	)	_
79-54	13310-13311	.	_

80-1	13312-13324	Specifically	_
80-2	13325-13326	,	_
80-3	13327-13331	over	_
80-4	13332-13333	a	_
80-5	13334-13342	10-trial	_
80-6	13343-13350	sliding	_
80-7	13351-13357	window	_
80-8	13358-13359	,	_
80-9	13360-13362	if	_
80-10	13363-13368	error	_
80-11	13369-13374	rates	_
80-12	13375-13379	were	_
80-13	13380-13385	below	_
80-14	13386-13389	0.3	_
80-15	13390-13391	,	_
80-16	13392-13396	then	_
80-17	13397-13401	task	_
80-18	13402-13412	difficulty	_
80-19	13413-13416	was	_
80-20	13417-13426	increased	_
80-21	13427-13428	,	_
80-22	13429-13432	and	_
80-23	13433-13435	if	_
80-24	13436-13439	the	_
80-25	13440-13444	rate	_
80-26	13445-13448	was	_
80-27	13449-13454	above	_
80-28	13455-13458	0.4	_
80-29	13459-13460	,	_
80-30	13461-13465	then	_
80-31	13466-13470	task	_
80-32	13471-13481	difficulty	_
80-33	13482-13485	was	_
80-34	13486-13495	decreased	_
80-35	13496-13497	.	_

81-1	13498-13502	This	_
81-2	13503-13507	task	_
81-3	13508-13515	feature	_
81-4	13516-13519	was	_
81-5	13520-13528	intended	_
81-6	13529-13531	to	_
81-7	13532-13538	induce	_
81-8	13539-13550	participant	_
81-9	13551-13562	uncertainty	_
81-10	13563-13568	about	_
81-11	13569-13574	trial	_
81-12	13575-13586	performance	_
81-13	13587-13592	until	_
81-14	13593-13601	feedback	_
81-15	13602-13610	delivery	_
81-16	13611-13612	(	_
81-17	13613-13617	i.e.	_
81-18	13618-13619	,	_
81-19	13620-13622	to	_
81-20	13623-13631	mitigate	_
81-21	13632-13635	the	_
81-22	13636-13650	self-detection	_
81-23	13651-13653	of	_
81-24	13654-13660	errors	_
81-25	13661-13662	)	_
81-26	13663-13664	.	_

82-1	13665-13670	While	_
82-2	13671-13674	the	_
82-3	13675-13682	dynamic	_
82-4	13683-13693	difficulty	_
82-5	13694-13706	manipulation	_
82-6	13707-13710	was	_
82-7	13711-13719	intended	_
82-8	13720-13722	to	_
82-9	13723-13735	consistently	_
82-10	13736-13744	maintain	_
82-11	13745-13750	error	_
82-12	13751-13756	rates	_
82-13	13757-13763	across	_
82-14	13764-13776	participants	_
82-15	13777-13780	and	_
82-16	13781-13787	across	_
82-17	13788-13791	the	_
82-18	13792-13795	six	_
82-19	13796-13808	neuroimaging	_
82-20	13809-13815	visits	_
82-21	13816-13817	,	_
82-22	13818-13821	one	_
82-23	13822-13832	behavioral	_
82-24	13833-13839	aspect	_
82-25	13840-13843	not	_
82-26	13844-13849	under	_
82-27	13850-13853	the	_
82-28	13854-13861	control	_
82-29	13862-13864	of	_
82-30	13865-13868	the	_
82-31	13869-13873	task	_
82-32	13874-13875	’	_
82-33	13876-13877	s	_
82-34	13878-13886	adaptive	_
82-35	13887-13896	algorithm	_
82-36	13897-13900	was	_
82-37	13901-13904	the	_
82-38	13905-13911	number	_
82-39	13912-13914	of	_
82-40	13915-13926	no-response	_
82-41	13927-13933	trials	_
82-42	13934-13935	(	_
82-43	13936-13942	errors	_
82-44	13943-13945	of	_
82-45	13946-13954	omission	_
82-46	13955-13956	)	_
82-47	13957-13958	,	_
82-48	13959-13964	which	_
82-49	13965-13972	reflect	_
82-50	13973-13982	momentary	_
82-51	13983-13989	lapses	_
82-52	13990-13992	of	_
82-53	13993-14002	attention	_
82-54	14003-14004	.	_

83-1	14005-14008	For	_
83-2	14009-14013	each	_
83-3	14014-14025	no-response	_
83-4	14026-14031	trial	_
83-5	14032-14043	encountered	_
83-6	14044-14045	,	_
83-7	14046-14049	the	_
83-8	14050-14058	adaptive	_
83-9	14059-14068	algorithm	_
83-10	14069-14076	reduced	_
83-11	14077-14080	the	_
83-12	14081-14089	targeted	_
83-13	14090-14096	number	_
83-14	14097-14099	of	_
83-15	14100-14107	correct	_
83-16	14108-14114	trials	_
83-17	14115-14117	by	_
83-18	14118-14121	one	_
83-19	14122-14123	.	_

84-1	14124-14129	Hence	_
84-2	14130-14131	,	_
84-3	14132-14135	the	_
84-4	14136-14143	percent	_
84-5	14144-14150	values	_
84-6	14151-14153	of	_
84-7	14154-14165	no-response	_
84-8	14166-14169	and	_
84-9	14170-14177	correct	_
84-10	14178-14184	trials	_
84-11	14185-14189	were	_
84-12	14190-14199	inversely	_
84-13	14200-14207	related	_
84-14	14208-14209	,	_
84-15	14210-14222	demonstrated	_
84-16	14223-14227	more	_
84-17	14228-14239	variability	_
84-18	14240-14246	across	_
84-19	14247-14259	participants	_
84-20	14260-14263	and	_
84-21	14264-14272	sessions	_
84-22	14273-14277	than	_
84-23	14278-14282	that	_
84-24	14283-14286	for	_
84-25	14287-14292	error	_
84-26	14293-14299	trials	_
84-27	14300-14301	,	_
84-28	14302-14305	and	_
84-29	14306-14310	thus	_
84-30	14311-14319	provided	_
84-31	14320-14321	a	_
84-32	14322-14332	convenient	_
84-33	14333-14343	behavioral	_
84-34	14344-14350	metric	_
84-35	14351-14353	to	_
84-36	14354-14360	assess	_
84-37	14361-14367	group-	_
84-38	14368-14371	and	_
84-39	14372-14384	drug-related	_
84-40	14385-14392	effects	_
84-41	14393-14395	on	_
84-42	14396-14401	these	_
84-43	14402-14405	two	_
84-44	14406-14415	dependent	_
84-45	14416-14425	variables	_
84-46	14426-14427	,	_
84-47	14428-14433	which	_
84-48	14434-14436	we	_
84-49	14437-14448	interpreted	_
84-50	14449-14451	as	_
84-51	14452-14457	gross	_
84-52	14458-14468	behavioral	_
84-53	14469-14477	measures	_
84-54	14478-14480	of	_
84-55	14481-14490	attention	_
84-56	14491-14492	.	_

85-1	14493-14498	Given	_
85-2	14499-14503	that	_
85-3	14504-14507	the	_
85-4	14508-14515	percent	_
85-5	14516-14518	of	_
85-6	14519-14530	no-response	_
85-7	14531-14534	and	_
85-8	14535-14542	correct	_
85-9	14543-14549	trials	_
85-10	14550-14554	were	_
85-11	14555-14556	“	_
85-12	14557-14563	mirror	_
85-13	14564-14570	images	_
85-14	14571-14572	”	_
85-15	14573-14575	of	_
85-16	14576-14580	each	_
85-17	14581-14586	other	_
85-18	14587-14588	,	_
85-19	14589-14593	only	_
85-20	14594-14605	no-response	_
85-21	14606-14611	trial	_
85-22	14612-14619	results	_
85-23	14620-14623	are	_
85-24	14624-14633	presented	_
85-25	14634-14635	.	_

86-1	14636-14640	Task	_
86-2	14641-14653	presentation	_
86-3	14654-14657	and	_
86-4	14658-14668	behavioral	_
86-5	14669-14680	performance	_
86-6	14681-14690	recording	_
86-7	14691-14695	were	_
86-8	14696-14706	controlled	_
86-9	14707-14709	by	_
86-10	14710-14717	E-prime	_
86-11	14718-14726	software	_
86-12	14727-14728	(	_
86-13	14729-14733	v1.2	_
86-14	14734-14735	,	_
86-15	14736-14746	Psychology	_
86-16	14747-14755	Software	_
86-17	14756-14761	Tools	_
86-18	14762-14763	)	_
86-19	14764-14765	.	_

87-1	14766-14778	Participants	_
87-2	14779-14788	completed	_
87-3	14789-14790	a	_
87-4	14791-14796	total	_
87-5	14797-14799	of	_
87-6	14800-14803	240	_
87-7	14804-14810	trials	_
87-8	14811-14813	in	_
87-9	14814-14818	four	_
87-10	14819-14824	9-min	_
87-11	14825-14829	runs	_
87-12	14830-14834	with	_
87-13	14835-14840	short	_
87-14	14841-14845	rest	_
87-15	14846-14853	periods	_
87-16	14854-14861	between	_
87-17	14862-14866	runs	_
87-18	14867-14868	1	_
87-19	14869-14871	to	_
87-20	14872-14873	2	_
87-21	14874-14877	and	_
87-22	14878-14879	3	_
87-23	14880-14882	to	_
87-24	14883-14884	4	_
87-25	14885-14888	and	_
87-26	14889-14890	a	_
87-27	14891-14897	longer	_
87-28	14898-14903	break	_
87-29	14904-14911	between	_
87-30	14912-14916	runs	_
87-31	14917-14918	2	_
87-32	14919-14922	and	_
87-33	14923-14924	3	_
87-34	14925-14926	(	_
87-35	14927-14933	during	_
87-36	14934-14939	which	_
87-37	14940-14941	a	_
87-38	14942-14953	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
87-39	14954-14964	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
87-40	14965-14968	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
87-41	14969-14972	was	_
87-42	14973-14982	collected	_
87-43	14983-14986	and	_
87-44	14987-14999	participants	_
87-45	15000-15004	were	_
87-46	15005-15015	instructed	_
87-47	15016-15018	to	_
87-48	15019-15024	relax	_
87-49	15025-15030	while	_
87-50	15031-15038	staying	_
87-51	15039-15041	as	_
87-52	15042-15047	still	_
87-53	15048-15050	as	_
87-54	15051-15059	possible	_
87-55	15060-15061	)	_
87-56	15062-15063	.	_

88-1	15064-15074	Behavioral	_
88-2	15075-15083	measures	_
88-3	15084-15085	:	_
88-4	15086-15097	Statistical	_
88-5	15098-15106	analysis	_
88-6	15107-15110	The	_
88-7	15111-15118	primary	_
88-8	15119-15129	behavioral	_
88-9	15130-15141	performance	_
88-10	15142-15150	measures	_
88-11	15151-15161	considered	_
88-12	15162-15166	from	_
88-13	15167-15170	the	_
88-14	15171-15175	task	_
88-15	15176-15180	were	_
88-16	15181-15184	RTs	_
88-17	15185-15188	and	_
88-18	15189-15192	the	_
88-19	15193-15200	percent	_
88-20	15201-15203	of	_
88-21	15204-15215	no-response	_
88-22	15216-15222	trials	_
88-23	15223-15224	.	_

89-1	15225-15227	To	_
89-2	15228-15237	replicate	_
89-3	15238-15246	outcomes	_
89-4	15247-15251	from	_
89-5	15252-15255	the	_
89-6	15256-15264	original	_
89-7	15265-15269	task	_
89-8	15270-15284	implementation	_
89-9	15285-15286	[	_
89-10	15287-15288	7	_
89-11	15289-15290	]	_
89-12	15291-15294	and	_
89-13	15295-15297	to	_
89-14	15298-15304	assess	_
89-15	15305-15309	task	_
89-16	15310-15320	engagement	_
89-17	15321-15322	,	_
89-18	15323-15325	we	_
89-19	15326-15334	analyzed	_
89-20	15335-15337	RT	_
89-21	15338-15342	data	_
89-22	15343-15345	in	_
89-23	15346-15347	a	_
89-24	15348-15356	FEEDBACK	_
89-25	15357-15358	[	_
89-26	15359-15370	informative	_
89-27	15371-15372	(	_
89-28	15373-15374	i	_
89-29	15375-15376	)	_
89-30	15377-15383	versus	_
89-31	15384-15398	noninformative	_
89-32	15399-15400	(	_
89-33	15401-15402	n	_
89-34	15403-15404	)	_
89-35	15405-15406	]	_
89-36	15407-15408	*	_
89-37	15409-15417	RESPONSE	_
89-38	15418-15419	[	_
89-39	15420-15427	correct	_
89-40	15428-15429	(	_
89-41	15430-15431	C	_
89-42	15432-15433	)	_
89-43	15434-15440	versus	_
89-44	15441-15446	error	_
89-45	15447-15448	(	_
89-46	15449-15450	E	_
89-47	15451-15452	)	_
89-48	15453-15454	]	_
89-49	15455-15472	repeated-measures	_
89-50	15473-15478	ANOVA	_
89-51	15479-15484	using	_
89-52	15485-15489	SPSS	_
89-53	15490-15491	(	_
89-54	15492-15495	v23	_
89-55	15496-15497	,	_
89-56	15498-15505	Chicago	_
89-57	15506-15507	,	_
89-58	15508-15510	IL	_
89-59	15511-15512	)	_
89-60	15513-15514	.	_

90-1	15515-15517	As	_
90-2	15518-15522	this	_
90-3	15523-15531	analysis	_
90-4	15532-15539	focused	_
90-5	15540-15542	on	_
90-6	15543-15546	the	_
90-7	15547-15554	overall	_
90-8	15555-15559	task	_
90-9	15560-15566	effect	_
90-10	15567-15568	(	_
90-11	15569-15571	as	_
90-12	15572-15579	opposed	_
90-13	15580-15582	to	_
90-14	15583-15599	session-specific	_
90-15	15600-15612	fluctuations	_
90-16	15613-15614	)	_
90-17	15615-15616	,	_
90-18	15617-15621	each	_
90-19	15622-15633	participant	_
90-20	15634-15635	’	_
90-21	15636-15637	s	_
90-22	15638-15640	RT	_
90-23	15641-15645	data	_
90-24	15646-15650	were	_
90-25	15651-15656	first	_
90-26	15657-15665	averaged	_
90-27	15666-15672	across	_
90-28	15673-15676	all	_
90-29	15677-15680	six	_
90-30	15681-15693	neuroimaging	_
90-31	15694-15700	visits	_
90-32	15701-15702	(	_
90-33	15703-15707	i.e.	_
90-34	15708-15709	,	_
90-35	15710-15719	collapsed	_
90-36	15720-15726	across	_
90-37	15727-15734	session	_
90-38	15735-15736	)	_
90-39	15737-15747	separately	_
90-40	15748-15751	for	_
90-41	15752-15756	each	_
90-42	15757-15762	trial	_
90-43	15763-15767	type	_
90-44	15768-15769	.	_

91-1	15770-15774	Main	_
91-2	15775-15778	and	_
91-3	15779-15790	interaction	_
91-4	15791-15798	effects	_
91-5	15799-15803	were	_
91-6	15804-15814	considered	_
91-7	15815-15816	.	_

92-1	15817-15819	To	_
92-2	15820-15832	characterize	_
92-3	15833-15838	group	_
92-4	15839-15846	effects	_
92-5	15847-15850	and	_
92-6	15851-15855	drug	_
92-7	15856-15863	effects	_
92-8	15864-15866	on	_
92-9	15867-15869	an	_
92-10	15870-15879	objective	_
92-11	15880-15887	measure	_
92-12	15888-15890	of	_
92-13	15891-15900	attention	_
92-14	15901-15902	,	_
92-15	15903-15905	we	_
92-16	15906-15914	analyzed	_
92-17	15915-15918	the	_
92-18	15919-15926	percent	_
92-19	15927-15929	of	_
92-20	15930-15941	no-response	_
92-21	15942-15948	trials	_
92-22	15949-15951	in	_
92-23	15952-15953	a	_
92-24	15954-15967	mixed-effects	_
92-25	15968-15973	ANOVA	_
92-26	15974-15975	,	_
92-27	15976-15985	including	_
92-28	15986-15993	factors	_
92-29	15994-15997	for	_
92-30	15998-16003	GROUP	_
92-31	16004-16005	(	_
92-32	16006-16013	between	_
92-33	16014-16026	participants	_
92-34	16027-16028	:	_
92-35	16029-16036	smokers	_
92-36	16037-16043	versus	_
92-37	16044-16054	nonsmokers	_
92-38	16055-16056	)	_
92-39	16057-16058	,	_
92-40	16059-16064	PATCH	_
92-41	16065-16066	(	_
92-42	16067-16073	within	_
92-43	16074-16086	participants	_
92-44	16087-16088	:	_
92-45	16089-16097	nicotine	_
92-46	16098-16104	versus	_
92-47	16105-16112	placebo	_
92-48	16113-16114	)	_
92-49	16115-16116	,	_
92-50	16117-16120	and	_
92-51	16121-16125	PILL	_
92-52	16126-16127	(	_
92-53	16128-16134	within	_
92-54	16135-16147	participants	_
92-55	16148-16149	:	_
92-56	16150-16158	pre-pill	_
92-57	16159-16160	,	_
92-58	16161-16172	varenicline	_
92-59	16173-16174	,	_
92-60	16175-16181	versus	_
92-61	16182-16189	placebo	_
92-62	16190-16191	)	_
92-63	16192-16193	.	_

93-1	16194-16198	Main	_
93-2	16199-16202	and	_
93-3	16203-16214	interaction	_
93-4	16215-16222	effects	_
93-5	16223-16227	were	_
93-6	16228-16238	considered	_
93-7	16239-16240	,	_
93-8	16241-16244	and	_
93-9	16245-16256	significant	_
93-10	16257-16269	interactions	_
93-11	16270-16279	involving	_
93-12	16280-16283	the	_
93-13	16284-16289	GROUP	_
93-14	16290-16296	factor	_
93-15	16297-16303	and/or	_
93-16	16304-16305	a	_
93-17	16306-16311	PATCH	_
93-18	16312-16316	main	_
93-19	16317-16323	effect	_
93-20	16324-16328	were	_
93-21	16329-16337	followed	_
93-22	16338-16340	by	_
93-23	16341-16353	within-group	_
93-24	16354-16355	,	_
93-25	16356-16373	repeated-measures	_
93-26	16374-16380	ANOVAs	_
93-27	16381-16390	including	_
93-28	16391-16396	PATCH	_
93-29	16397-16400	and	_
93-30	16401-16405	PILL	_
93-31	16406-16408	as	_
93-32	16409-16416	factors	_
93-33	16417-16418	.	_

94-1	16419-16437	Geisser-Greenhouse	_
94-2	16438-16449	corrections	_
94-3	16450-16453	for	_
94-4	16454-16464	violations	_
94-5	16465-16467	of	_
94-6	16468-16478	sphericity	_
94-7	16479-16483	were	_
94-8	16484-16488	used	_
94-9	16489-16493	when	_
94-10	16494-16505	considering	_
94-11	16506-16513	effects	_
94-12	16514-16523	involving	_
94-13	16524-16527	the	_
94-14	16528-16532	PILL	_
94-15	16533-16539	factor	_
94-16	16540-16541	(	_
94-17	16542-16547	three	_
94-18	16548-16554	levels	_
94-19	16555-16556	)	_
94-20	16557-16558	.	_

95-1	16559-16567	Pairwise	_
95-2	16568-16577	follow-up	_
95-3	16578-16579	t	_
95-4	16580-16585	tests	_
95-5	16586-16595	comparing	_
95-6	16596-16604	nicotine	_
95-7	16605-16611	versus	_
95-8	16612-16619	placebo	_
95-9	16620-16625	PATCH	_
95-10	16626-16637	differences	_
95-11	16638-16639	(	_
95-12	16640-16642	in	_
95-13	16643-16646	the	_
95-14	16647-16654	absence	_
95-15	16655-16657	of	_
95-16	16658-16669	varenicline	_
95-17	16670-16675	under	_
95-18	16676-16683	placebo	_
95-19	16684-16688	pill	_
95-20	16689-16699	conditions	_
95-21	16700-16701	)	_
95-22	16702-16705	and	_
95-23	16706-16715	assessing	_
95-24	16716-16727	varenicline	_
95-25	16728-16734	versus	_
95-26	16735-16742	placebo	_
95-27	16743-16747	PILL	_
95-28	16748-16759	differences	_
95-29	16760-16761	(	_
95-30	16762-16764	in	_
95-31	16765-16768	the	_
95-32	16769-16776	absence	_
95-33	16777-16779	of	_
95-34	16780-16788	nicotine	_
95-35	16789-16794	under	_
95-36	16795-16802	placebo	_
95-37	16803-16808	patch	_
95-38	16809-16819	conditions	_
95-39	16820-16821	)	_
95-40	16822-16826	were	_
95-41	16827-16847	Bonferroni-corrected	_
95-42	16848-16849	.	_

96-1	16850-16853	All	_
96-2	16854-16866	participants	_
96-3	16867-16868	(	_
96-4	16869-16870	N	_
96-5	16871-16872	=	_
96-6	16873-16875	44	_
96-7	16876-16877	)	_
96-8	16878-16890	sufficiently	_
96-9	16891-16900	performed	_
96-10	16901-16904	the	_
96-11	16905-16909	task	_
96-12	16910-16913	and	_
96-13	16914-16925	contributed	_
96-14	16926-16936	behavioral	_
96-15	16937-16941	data	_
96-16	16942-16944	to	_
96-17	16945-16950	these	_
96-18	16951-16959	analyses	_
96-19	16960-16961	.	_

97-1	16962-16965	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
97-2	16966-16970	data	_
97-3	16971-16982	acquisition	_
97-4	16983-16986	and	_
97-5	16987-16995	analysis	_
97-6	16996-16999	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
97-7	17000-17004	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
97-8	17005-17009	were	_
97-9	17010-17019	collected	_
97-10	17020-17022	on	_
97-11	17023-17024	a	_
97-12	17025-17032	Siemens	_
97-13	17033-17035	3T	http://maven.renci.org/NeuroBridge/neurobridge#Thing
97-14	17036-17044	Magnetom	_
97-15	17045-17052	Allegra	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
97-16	17053-17060	scanner	_
97-17	17061-17062	(	_
97-18	17063-17071	Erlangen	_
97-19	17072-17073	,	_
97-20	17074-17081	Germany	_
97-21	17082-17083	)	_
97-22	17084-17085	.	_

98-1	17086-17092	During	_
98-2	17093-17097	task	_
98-3	17098-17109	performance	_
98-4	17110-17111	,	_
98-5	17112-17114	33	_
98-6	17115-17121	slices	_
98-7	17122-17123	(	_
98-8	17124-17125	5	_
98-9	17126-17128	mm	_
98-10	17129-17134	thick	_
98-11	17135-17136	)	_
98-12	17137-17141	were	_
98-13	17142-17150	obtained	_
98-14	17151-17153	in	_
98-15	17154-17157	the	_
98-16	17158-17166	sagittal	_
98-17	17167-17172	plane	_
98-18	17173-17178	using	_
98-19	17179-17180	a	_
98-20	17181-17183	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
98-21	17184-17185	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
98-22	17186-17195	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
98-23	17196-17197	,	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
98-24	17198-17209	single-shot	_
98-25	17210-17211	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
98-26	17212-17225	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
98-27	17226-17227	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
98-28	17228-17231	EPI	_
98-29	17232-17240	sequence	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
98-30	17241-17250	sensitive	_
98-31	17251-17253	to	_
98-32	17254-17258	BOLD	_
98-33	17259-17266	effects	_
98-34	17267-17268	[	_
98-35	17269-17272	272	_
98-36	17273-17280	volumes	_
98-37	17281-17284	per	_
98-38	17285-17288	run	_
98-39	17289-17290	,	_
98-40	17291-17301	repetition	_
98-41	17302-17306	time	_
98-42	17307-17308	=	_
98-43	17309-17313	2000	_
98-44	17314-17316	ms	_
98-45	17317-17318	(	_
98-46	17319-17325	332-ms	_
98-47	17326-17331	delay	_
98-48	17332-17333	)	_
98-49	17334-17335	,	_
98-50	17336-17340	echo	_
98-51	17341-17345	time	_
98-52	17346-17347	=	_
98-53	17348-17350	27	_
98-54	17351-17353	ms	_
98-55	17354-17355	,	_
98-56	17356-17360	flip	_
98-57	17361-17366	angle	_
98-58	17367-17368	=	_
98-59	17369-17372	80°	_
98-60	17373-17374	,	_
98-61	17375-17380	field	_
98-62	17381-17383	of	_
98-63	17384-17388	view	_
98-64	17389-17390	=	_
98-65	17391-17394	220	_
98-66	17395-17397	mm	_
98-67	17398-17400	in	_
98-68	17401-17402	a	_
98-69	17403-17405	64	_
98-70	17406-17407	×	_
98-71	17408-17410	64	_
98-72	17411-17417	matrix	_
98-73	17418-17419	]	_
98-74	17420-17421	.	_

99-1	17422-17424	As	_
99-2	17425-17437	simultaneous	_
99-3	17438-17460	electroencephalography	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalograph
99-4	17461-17462	(	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalograph
99-5	17463-17466	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalograph
99-6	17467-17468	)	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalograph
99-7	17469-17473	data	_
99-8	17474-17478	were	_
99-9	17479-17483	also	_
99-10	17484-17492	acquired	_
99-11	17493-17494	(	_
99-12	17495-17498	not	_
99-13	17499-17508	discussed	_
99-14	17509-17516	further	_
99-15	17517-17518	)	_
99-16	17519-17520	,	_
99-17	17521-17529	sagittal	_
99-18	17530-17536	images	_
99-19	17537-17541	were	_
99-20	17542-17551	collected	_
99-21	17552-17556	with	_
99-22	17557-17558	a	_
99-23	17559-17564	delay	_
99-24	17565-17572	between	_
99-25	17573-17579	volume	_
99-26	17580-17592	acquisitions	_
99-27	17593-17595	to	_
99-28	17596-17599	aid	_
99-29	17600-17616	scanner-artifact	_
99-30	17617-17624	removal	_
99-31	17625-17629	from	_
99-32	17630-17633	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
99-33	17634-17644	recordings	_
99-34	17645-17646	.	_

100-1	17647-17658	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
100-2	17659-17669	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
100-3	17670-17676	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
100-4	17677-17681	were	_
100-5	17682-17690	obtained	_
100-6	17691-17696	using	_
100-7	17697-17698	a	_
100-8	17699-17721	magnetization-prepared	_
100-9	17722-17727	rapid	_
100-10	17728-17741	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
100-11	17742-17750	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
100-12	17751-17752	(	_
100-13	17753-17759	MPRAGE	_
100-14	17760-17761	:	_
100-15	17762-17772	repetition	_
100-16	17773-17777	time	_
100-17	17778-17779	=	_
100-18	17780-17784	2500	_
100-19	17785-17787	ms	_
100-20	17788-17789	;	_
100-21	17790-17794	echo	_
100-22	17795-17799	time	_
100-23	17800-17801	=	_
100-24	17802-17806	4.38	_
100-25	17807-17809	ms	_
100-26	17810-17811	;	_
100-27	17812-17816	flip	_
100-28	17817-17822	angle	_
100-29	17823-17824	=	_
100-30	17825-17827	8°	_
100-31	17828-17829	;	_
100-32	17830-17835	voxel	_
100-33	17836-17840	size	_
100-34	17841-17842	=	_
100-35	17843-17844	1	_
100-36	17845-17848	mm3	_
100-37	17849-17850	)	_
100-38	17851-17852	.	_

101-1	17853-17865	Neuroimaging	_
101-2	17866-17870	data	_
101-3	17871-17875	were	_
101-4	17876-17888	preprocessed	_
101-5	17889-17892	and	_
101-6	17893-17901	analyzed	_
101-7	17902-17907	using	_
101-8	17908-17916	Analysis	_
101-9	17917-17919	of	_
101-10	17920-17930	Functional	_
101-11	17931-17942	NeuroImages	_
101-12	17943-17944	(	_
101-13	17945-17949	AFNI	_
101-14	17950-17951	)	_
101-15	17952-17953	(	_
101-16	17954-17961	version	_
101-17	17962-17969	16.3.18	_
101-18	17970-17971	;	_
101-19	17972-17976	http	_
101-20	17977-17978	:	_
101-21	17979-18004	//afni.nimh.nih.gov/afni/	_
101-22	18005-18006	)	_
101-23	18007-18008	.	_

102-1	18009-18019	Functional	_
102-2	18020-18026	images	_
102-3	18027-18031	were	_
102-4	18032-18037	slice	_
102-5	18038-18043	time–	_
102-6	18044-18047	and	_
102-7	18048-18064	motion-corrected	_
102-8	18065-18066	,	_
102-9	18067-18077	registered	_
102-10	18078-18080	to	_
102-11	18081-18084	the	_
102-12	18085-18095	anatomical	_
102-13	18096-18102	volume	_
102-14	18103-18104	,	_
102-15	18105-18115	normalized	_
102-16	18116-18120	into	_
102-17	18121-18130	Talairach	_
102-18	18131-18136	space	_
102-19	18137-18138	(	_
102-20	18139-18143	3-mm	_
102-21	18144-18153	isotropic	_
102-22	18154-18160	voxels	_
102-23	18161-18162	,	_
102-24	18163-18165	27	_
102-25	18166-18168	μl	_
102-26	18169-18170	)	_
102-27	18171-18172	,	_
102-28	18173-18176	and	_
102-29	18177-18186	spatially	_
102-30	18187-18194	blurred	_
102-31	18195-18197	to	_
102-32	18198-18202	7-mm	_
102-33	18203-18207	FWHM	_
102-34	18208-18209	(	_
102-35	18210-18214	AFNI	_
102-36	18215-18216	’	_
102-37	18217-18218	s	_
102-38	18219-18231	3dBlurToFWHM	_
102-39	18232-18233	)	_
102-40	18234-18235	.	_

103-1	18236-18245	Following	_
103-2	18246-18252	motion	_
103-3	18253-18263	correction	_
103-4	18264-18265	,	_
103-5	18266-18276	functional	_
103-6	18277-18291	volumes/frames	_
103-7	18292-18296	with	_
103-8	18297-18298	>	_
103-9	18299-18306	0.35-mm	_
103-10	18307-18316	Euclidean	_
103-11	18317-18321	norm	_
103-12	18322-18326	mean	_
103-13	18327-18339	displacement	_
103-14	18340-18344	were	_
103-15	18345-18353	censored	_
103-16	18354-18359	along	_
103-17	18360-18364	with	_
103-18	18365-18368	the	_
103-19	18369-18380	immediately	_
103-20	18381-18389	adjacent	_
103-21	18390-18397	volumes	_
103-22	18398-18399	.	_

104-1	18400-18405	Those	_
104-2	18406-18413	volumes	_
104-3	18414-18418	with	_
104-4	18419-18424	fewer	_
104-5	18425-18429	than	_
104-6	18430-18435	three	_
104-7	18436-18446	contiguous	_
104-8	18447-18457	uncensored	_
104-9	18458-18467	neighbors	_
104-10	18468-18472	were	_
104-11	18473-18477	also	_
104-12	18478-18485	flagged	_
104-13	18486-18489	for	_
104-14	18490-18499	censoring	_
104-15	18500-18501	.	_

105-1	18502-18512	Individual	_
105-2	18513-18521	scanning	_
105-3	18522-18530	sessions	_
105-4	18531-18535	were	_
105-5	18536-18544	excluded	_
105-6	18545-18549	from	_
105-7	18550-18557	imaging	_
105-8	18558-18566	analyses	_
105-9	18567-18569	if	_
105-10	18570-18574	more	_
105-11	18575-18579	than	_
105-12	18580-18582	25	_
105-13	18583-18584	%	_
105-14	18585-18587	of	_
105-15	18588-18591	the	_
105-16	18592-18602	functional	_
105-17	18603-18610	volumes	_
105-18	18611-18615	were	_
105-19	18616-18631	motion-censored	_
105-20	18632-18633	.	_

106-1	18634-18638	This	_
106-2	18639-18647	resulted	_
106-3	18648-18650	in	_
106-4	18651-18654	the	_
106-5	18655-18664	exclusion	_
106-6	18665-18667	of	_
106-7	18668-18673	three	_
106-8	18674-18678	male	_
106-9	18679-18691	participants	_
106-10	18692-18693	(	_
106-11	18694-18697	two	_
106-12	18698-18705	smokers	_
106-13	18706-18709	and	_
106-14	18710-18713	one	_
106-15	18714-18723	nonsmoker	_
106-16	18724-18725	)	_
106-17	18726-18730	from	_
106-18	18731-18738	further	_
106-19	18739-18747	analyses	_
106-20	18748-18753	given	_
106-21	18754-18758	that	_
106-22	18759-18760	a	_
106-23	18761-18769	majority	_
106-24	18770-18772	of	_
106-25	18773-18778	their	_
106-26	18779-18782	six	_
106-27	18783-18795	neuroimaging	_
106-28	18796-18804	sessions	_
106-29	18805-18809	were	_
106-30	18810-18817	flagged	_
106-31	18818-18820	as	_
106-32	18821-18825	high	_
106-33	18826-18832	motion	_
106-34	18833-18834	.	_

107-1	18835-18838	Six	_
107-2	18839-18849	additional	_
107-3	18850-18862	participants	_
107-4	18863-18866	had	_
107-5	18867-18874	between	_
107-6	18875-18878	one	_
107-7	18879-18882	and	_
107-8	18883-18888	three	_
107-9	18889-18897	scanning	_
107-10	18898-18906	sessions	_
107-11	18907-18916	discarded	_
107-12	18917-18921	from	_
107-13	18922-18929	further	_
107-14	18930-18938	analysis	_
107-15	18939-18946	because	_
107-16	18947-18949	of	_
107-17	18950-18956	motion	_
107-18	18957-18958	.	_

108-1	18959-18964	Hence	_
108-2	18965-18966	,	_
108-3	18967-18969	41	_
108-4	18970-18982	participants	_
108-5	18983-18984	(	_
108-6	18985-18987	22	_
108-7	18988-18995	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
108-8	18996-18999	and	_
108-9	19000-19002	19	_
108-10	19003-19013	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
108-11	19014-19015	)	_
108-12	19016-19027	contributed	_
108-13	19028-19040	neuroimaging	_
108-14	19041-19045	data	_
108-15	19046-19048	to	_
108-16	19049-19054	these	_
108-17	19055-19063	analyses	_
108-18	19064-19065	.	_

109-1	19066-19076	Functional	_
109-2	19077-19081	time	_
109-3	19082-19088	series	_
109-4	19089-19093	were	_
109-5	19094-19104	normalized	_
109-6	19105-19107	to	_
109-7	19108-19115	percent	_
109-8	19116-19122	signal	_
109-9	19123-19129	change	_
109-10	19130-19133	and	_
109-11	19134-19143	submitted	_
109-12	19144-19146	to	_
109-13	19147-19157	voxel-wise	_
109-14	19158-19166	multiple	_
109-15	19167-19177	regression	_
109-16	19178-19179	.	_

110-1	19180-19182	In	_
110-2	19183-19186	the	_
110-3	19187-19198	first-level	_
110-4	19199-19206	general	_
110-5	19207-19213	linear	_
110-6	19214-19219	model	_
110-7	19220-19221	(	_
110-8	19222-19225	GLM	_
110-9	19226-19227	)	_
110-10	19228-19229	,	_
110-11	19230-19232	we	_
110-12	19233-19241	included	_
110-13	19242-19246	five	_
110-14	19247-19255	separate	_
110-15	19256-19268	task-related	_
110-16	19269-19279	regressors	_
110-17	19280-19282	as	_
110-18	19283-19290	impulse	_
110-19	19291-19300	functions	_
110-20	19301-19312	time-locked	_
110-21	19313-19315	to	_
110-22	19316-19319	the	_
110-23	19320-19325	onset	_
110-24	19326-19328	of	_
110-25	19329-19337	feedback	_
110-26	19338-19350	presentation	_
110-27	19351-19352	(	_
110-28	19353-19355	iC	_
110-29	19356-19357	,	_
110-30	19358-19360	iE	_
110-31	19361-19362	,	_
110-32	19363-19365	nC	_
110-33	19366-19367	,	_
110-34	19368-19370	nE	_
110-35	19371-19372	,	_
110-36	19373-19376	and	_
110-37	19377-19379	no	_
110-38	19380-19388	response	_
110-39	19389-19395	trials	_
110-40	19396-19397	)	_
110-41	19398-19399	.	_

111-1	19400-19405	These	_
111-2	19406-19416	regressors	_
111-3	19417-19421	were	_
111-4	19422-19431	convolved	_
111-5	19432-19436	with	_
111-6	19437-19438	a	_
111-7	19439-19444	model	_
111-8	19445-19456	hemodynamic	_
111-9	19457-19465	response	_
111-10	19466-19467	(	_
111-11	19468-19473	gamma	_
111-12	19474-19475	)	_
111-13	19476-19484	function	_
111-14	19485-19488	and	_
111-15	19489-19492	its	_
111-16	19493-19501	temporal	_
111-17	19502-19513	derivatives	_
111-18	19514-19515	.	_

112-1	19516-19526	Regressors	_
112-2	19527-19529	of	_
112-3	19530-19532	no	_
112-4	19533-19541	interest	_
112-5	19542-19546	also	_
112-6	19547-19555	included	_
112-7	19556-19558	in	_
112-8	19559-19562	the	_
112-9	19563-19566	GLM	_
112-10	19567-19571	were	_
112-11	19572-19575	the	_
112-12	19576-19579	six	_
112-13	19580-19597	motion-correction	_
112-14	19598-19608	parameters	_
112-15	19609-19611	as	_
112-16	19612-19616	well	_
112-17	19617-19619	as	_
112-18	19620-19632	fourth-order	_
112-19	19633-19643	polynomial	_
112-20	19644-19654	regressors	_
112-21	19655-19657	to	_
112-22	19658-19665	capture	_
112-23	19666-19674	residual	_
112-24	19675-19679	head	_
112-25	19680-19686	motion	_
112-26	19687-19690	and	_
112-27	19691-19699	baseline	_
112-28	19700-19706	trends	_
112-29	19707-19709	in	_
112-30	19710-19713	the	_
112-31	19714-19718	BOLD	_
112-32	19719-19725	signal	_
112-33	19726-19727	,	_
112-34	19728-19740	respectively	_
112-35	19741-19742	.	_

113-1	19743-19745	As	_
113-2	19746-19749	the	_
113-3	19750-19754	time	_
113-4	19755-19761	series	_
113-5	19762-19766	were	_
113-6	19767-19773	scaled	_
113-7	19774-19776	by	_
113-8	19777-19780	the	_
113-9	19781-19791	voxel-wise	_
113-10	19792-19796	mean	_
113-11	19797-19798	,	_
113-12	19799-19808	resulting	_
113-13	19809-19819	regression	_
113-14	19820-19821	(	_
113-15	19822-19823	β	_
113-16	19824-19825	)	_
113-17	19826-19838	coefficients	_
113-18	19839-19840	,	_
113-19	19841-19851	calculated	_
113-20	19852-19855	per	_
113-21	19856-19865	regressor	_
113-22	19866-19867	,	_
113-23	19868-19879	participant	_
113-24	19880-19881	,	_
113-25	19882-19885	and	_
113-26	19886-19893	session	_
113-27	19894-19895	,	_
113-28	19896-19900	were	_
113-29	19901-19912	interpreted	_
113-30	19913-19915	as	_
113-31	19916-19918	an	_
113-32	19919-19932	approximation	_
113-33	19933-19935	of	_
113-34	19936-19943	percent	_
113-35	19944-19948	BOLD	_
113-36	19949-19955	signal	_
113-37	19956-19962	change	_
113-38	19963-19964	(	_
113-39	19965-19966	%	_
113-40	19967-19971	BOLD	_
113-41	19972-19973	Δ	_
113-42	19974-19975	)	_
113-43	19976-19980	from	_
113-44	19981-19984	the	_
113-45	19985-19993	implicit	_
113-46	19994-20002	baseline	_
113-47	20003-20004	.	_

114-1	20005-20009	Task	_
114-2	20010-20017	effects	_
114-3	20018-20020	To	_
114-4	20021-20030	replicate	_
114-5	20031-20039	outcomes	_
114-6	20040-20044	from	_
114-7	20045-20048	the	_
114-8	20049-20057	original	_
114-9	20058-20062	task	_
114-10	20063-20077	implementation	_
114-11	20078-20081	and	_
114-12	20082-20084	to	_
114-13	20085-20093	identify	_
114-14	20094-20101	regions	_
114-15	20102-20109	showing	_
114-16	20110-20122	differential	_
114-17	20123-20131	activity	_
114-18	20132-20141	following	_
114-19	20142-20153	performance	_
114-20	20154-20162	feedback	_
114-21	20163-20164	,	_
114-22	20165-20167	we	_
114-23	20168-20178	calculated	_
114-24	20179-20187	contrast	_
114-25	20188-20194	images	_
114-26	20195-20202	between	_
114-27	20203-20211	negative	_
114-28	20212-20215	and	_
114-29	20216-20224	positive	_
114-30	20225-20233	feedback	_
114-31	20234-20235	(	_
114-32	20236-20238	iE	_
114-33	20239-20240	−	_
114-34	20241-20243	iC	_
114-35	20244-20246	βs	_
114-36	20247-20248	)	_
114-37	20249-20250	.	_

115-1	20251-20261	Individual	_
115-2	20262-20273	participant	_
115-3	20274-20275	’	_
115-4	20276-20277	s	_
115-5	20278-20286	contrast	_
115-6	20287-20293	images	_
115-7	20294-20298	were	_
115-8	20299-20304	first	_
115-9	20305-20313	averaged	_
115-10	20314-20320	across	_
115-11	20321-20324	all	_
115-12	20325-20333	sessions	_
115-13	20334-20337	and	_
115-14	20338-20342	then	_
115-15	20343-20352	submitted	_
115-16	20353-20355	to	_
115-17	20356-20357	a	_
115-18	20358-20369	group-level	_
115-19	20370-20371	,	_
115-20	20372-20383	whole-brain	_
115-21	20384-20385	,	_
115-22	20386-20396	one-sample	_
115-23	20397-20398	t	_
115-24	20399-20403	test	_
115-25	20404-20405	(	_
115-26	20406-20409	two	_
115-27	20410-20416	tailed	_
115-28	20417-20418	,	_
115-29	20419-20428	3dTtest++	_
115-30	20429-20430	)	_
115-31	20431-20432	.	_

116-1	20433-20436	The	_
116-2	20437-20446	resulting	_
116-3	20447-20458	statistical	_
116-4	20459-20463	maps	_
116-5	20464-20468	were	_
116-6	20469-20480	thresholded	_
116-7	20481-20491	correcting	_
116-8	20492-20495	for	_
116-9	20496-20507	family-wise	_
116-10	20508-20513	error	_
116-11	20514-20516	at	_
116-12	20517-20527	Pcorrected	_
116-13	20528-20529	<	_
116-14	20530-20535	0.001	_
116-15	20536-20537	[	_
116-16	20538-20549	Pvoxel-wise	_
116-17	20550-20551	<	_
116-18	20552-20558	0.0001	_
116-19	20559-20560	,	_
116-20	20561-20568	cluster	_
116-21	20569-20575	extent	_
116-22	20576-20577	:	_
116-23	20578-20580	15	_
116-24	20581-20587	voxels	_
116-25	20588-20589	,	_
116-26	20590-20596	51,704	_
116-27	20597-20603	voxels	_
116-28	20604-20606	in	_
116-29	20607-20610	the	_
116-30	20611-20622	whole-brain	_
116-31	20623-20627	mask	_
116-32	20628-20629	,	_
116-33	20630-20640	3dClustSim	_
116-34	20641-20645	with	_
116-35	20646-20649	the	_
116-36	20650-20657	spatial	_
116-37	20658-20673	autocorrelation	_
116-38	20674-20682	function	_
116-39	20683-20693	correction	_
116-40	20694-20695	]	_
116-41	20696-20697	.	_

117-1	20698-20701	For	_
117-2	20702-20711	graphical	_
117-3	20712-20723	examination	_
117-4	20724-20727	and	_
117-5	20728-20737	follow-up	_
117-6	20738-20746	analyses	_
117-7	20747-20748	,	_
117-8	20749-20751	we	_
117-9	20752-20761	extracted	_
117-10	20762-20765	the	_
117-11	20766-20770	mean	_
117-12	20771-20772	β	_
117-13	20773-20785	coefficients	_
117-14	20786-20796	associated	_
117-15	20797-20801	with	_
117-16	20802-20810	specific	_
117-17	20811-20815	task	_
117-18	20816-20822	events	_
117-19	20823-20824	(	_
117-20	20825-20827	iE	_
117-21	20828-20829	,	_
117-22	20830-20832	iC	_
117-23	20833-20834	,	_
117-24	20835-20837	nE	_
117-25	20838-20839	,	_
117-26	20840-20843	and	_
117-27	20844-20846	nC	_
117-28	20847-20848	)	_
117-29	20849-20852	and	_
117-30	20853-20856	the	_
117-31	20857-20858	[	_
117-32	20859-20861	iE	_
117-33	20862-20863	−	_
117-34	20864-20866	iC	_
117-35	20867-20868	]	_
117-36	20869-20877	contrast	_
117-37	20878-20884	values	_
117-38	20885-20889	from	_
117-39	20890-20893	the	_
117-40	20894-20904	identified	_
117-41	20905-20917	task-related	_
117-42	20918-20931	clusters/ROIs	_
117-43	20932-20934	by	_
117-44	20935-20944	averaging	_
117-45	20945-20951	across	_
117-46	20952-20955	all	_
117-47	20956-20962	voxels	_
117-48	20963-20969	within	_
117-49	20970-20974	each	_
117-50	20975-20983	separate	_
117-51	20984-20987	ROI	_
117-52	20988-20989	.	_

118-1	20990-20992	We	_
118-2	20993-21002	performed	_
118-3	21003-21014	exploratory	_
118-4	21015-21024	bivariate	_
118-5	21025-21032	Pearson	_
118-6	21033-21034	’	_
118-7	21035-21036	s	_
118-8	21037-21049	correlations	_
118-9	21050-21057	between	_
118-10	21058-21061	the	_
118-11	21062-21070	contrast	_
118-12	21071-21077	values	_
118-13	21078-21079	(	_
118-14	21080-21082	iE	_
118-15	21083-21084	−	_
118-16	21085-21087	iC	_
118-17	21088-21090	βs	_
118-18	21091-21092	)	_
118-19	21093-21097	from	_
118-20	21098-21103	pairs	_
118-21	21104-21106	of	_
118-22	21107-21117	identified	_
118-23	21118-21122	ROIs	_
118-24	21123-21125	to	_
118-25	21126-21133	examine	_
118-26	21134-21137	the	_
118-27	21138-21150	relationship	_
118-28	21151-21158	between	_
118-29	21159-21162	the	_
118-30	21163-21179	feedback-related	_
118-31	21180-21192	responsivity	_
118-32	21193-21195	of	_
118-33	21196-21199	the	_
118-34	21200-21208	habenula	_
118-35	21209-21210	,	_
118-36	21211-21217	insula	_
118-37	21218-21219	,	_
118-38	21220-21223	and	_
118-39	21224-21231	ventral	_
118-40	21232-21240	striatum	_
118-41	21241-21242	.	_

119-1	21243-21248	These	_
119-2	21249-21260	exploratory	_
119-3	21261-21272	correlation	_
119-4	21273-21281	analyses	_
119-5	21282-21286	were	_
119-6	21287-21290	not	_
119-7	21291-21312	Bonferronni-corrected	_
119-8	21313-21316	for	_
119-9	21317-21325	multiple	_
119-10	21326-21337	comparisons	_
119-11	21338-21339	.	_

120-1	21340-21345	Group	_
120-2	21346-21353	effects	_
120-3	21354-21356	To	_
120-4	21357-21369	characterize	_
120-5	21370-21380	functional	_
120-6	21381-21392	alterations	_
120-7	21393-21399	linked	_
120-8	21400-21404	with	_
120-9	21405-21406	a	_
120-10	21407-21414	chronic	_
120-11	21415-21422	smoking	_
120-12	21423-21430	history	_
120-13	21431-21432	,	_
120-14	21433-21435	we	_
120-15	21436-21444	compared	_
120-16	21445-21461	session-averaged	_
120-17	21462-21463	(	_
120-18	21464-21466	iE	_
120-19	21467-21468	−	_
120-20	21469-21471	iC	_
120-21	21472-21473	)	_
120-22	21474-21482	contrast	_
120-23	21483-21489	images	_
120-24	21490-21497	between	_
120-25	21498-21505	smokers	_
120-26	21506-21509	and	_
120-27	21510-21520	nonsmokers	_
120-28	21521-21523	in	_
120-29	21524-21525	a	_
120-30	21526-21536	two-tailed	_
120-31	21537-21556	independent-samples	_
120-32	21557-21558	t	_
120-33	21559-21563	test	_
120-34	21564-21565	(	_
120-35	21566-21575	3dTtest++	_
120-36	21576-21577	)	_
120-37	21578-21579	.	_

121-1	21580-21585	Given	_
121-2	21586-21589	our	_
121-3	21590-21591	a	_
121-4	21592-21598	priori	_
121-5	21599-21604	focus	_
121-6	21605-21607	on	_
121-7	21608-21613	brain	_
121-8	21614-21621	regions	_
121-9	21622-21632	previously	_
121-10	21633-21639	linked	_
121-11	21640-21644	with	_
121-12	21645-21654	addiction	_
121-13	21655-21656	,	_
121-14	21657-21665	nicotine	_
121-15	21666-21676	withdrawal	_
121-16	21677-21678	,	_
121-17	21679-21682	and	_
121-18	21683-21691	feedback	_
121-19	21692-21702	processing	_
121-20	21703-21705	in	_
121-21	21706-21709	the	_
121-22	21710-21713	MCL	_
121-23	21714-21723	circuitry	_
121-24	21724-21725	,	_
121-25	21726-21728	we	_
121-26	21729-21736	applied	_
121-27	21737-21738	a	_
121-28	21739-21750	family-wise	_
121-29	21751-21756	error	_
121-30	21757-21767	correction	_
121-31	21768-21769	(	_
121-32	21770-21780	Pcorrected	_
121-33	21781-21782	<	_
121-34	21783-21787	0.05	_
121-35	21788-21789	)	_
121-36	21790-21796	within	_
121-37	21797-21798	a	_
121-38	21799-21808	composite	_
121-39	21809-21813	mask	_
121-40	21814-21816	of	_
121-41	21817-21825	interest	_
121-42	21826-21836	consisting	_
121-43	21837-21839	of	_
121-44	21840-21843	the	_
121-45	21844-21853	bilateral	_
121-46	21854-21861	nucleus	_
121-47	21862-21871	accumbens	_
121-48	21872-21873	,	_
121-49	21874-21881	caudate	_
121-50	21882-21883	,	_
121-51	21884-21891	putamen	_
121-52	21892-21893	,	_
121-53	21894-21902	pallidum	_
121-54	21903-21904	,	_
121-55	21905-21913	anterior	_
121-56	21914-21920	insula	_
121-57	21921-21922	,	_
121-58	21923-21931	anterior	_
121-59	21932-21941	cingulate	_
121-60	21942-21943	,	_
121-61	21944-21950	middle	_
121-62	21951-21959	anterior	_
121-63	21960-21969	cingulate	_
121-64	21970-21971	,	_
121-65	21972-21983	subcallosal	_
121-66	21984-21993	cingulate	_
121-67	21994-21995	,	_
121-68	21996-21999	and	_
121-69	22000-22008	habenula	_
121-70	22009-22016	regions	_
121-71	22017-22018	(	_
121-72	22019-22022	fig	_
121-73	22023-22024	.	_

122-1	22025-22027	S3	_
122-2	22028-22029	)	_
122-3	22030-22031	.	_

123-1	22032-22035	All	_
123-2	22036-22046	anatomical	_
123-3	22047-22052	masks	_
123-4	22053-22057	came	_
123-5	22058-22062	from	_
123-6	22063-22066	the	_
123-7	22067-22072	Desai	_
123-8	22073-22080	maximum	_
123-9	22081-22092	probability	_
123-10	22093-22096	map	_
123-11	22097-22098	,	_
123-12	22099-22103	with	_
123-13	22104-22107	the	_
123-14	22108-22117	exception	_
123-15	22118-22120	of	_
123-16	22121-22124	the	_
123-17	22125-22133	habenula	_
123-18	22134-22138	mask	_
123-19	22139-22143	that	_
123-20	22144-22147	was	_
123-21	22148-22155	defined	_
123-22	22156-22158	by	_
123-23	22159-22166	placing	_
123-24	22167-22171	3-mm	_
123-25	22172-22178	radius	_
123-26	22179-22186	spheres	_
123-27	22187-22193	around	_
123-28	22194-22198	left	_
123-29	22199-22202	and	_
123-30	22203-22208	right	_
123-31	22209-22219	hemisphere	_
123-32	22220-22231	coordinates	_
123-33	22232-22242	previously	_
123-34	22243-22251	reported	_
123-35	22252-22255	for	_
123-36	22256-22259	the	_
123-37	22260-22266	motion	_
123-38	22267-22277	prediction	_
123-39	22278-22282	task	_
123-40	22283-22284	.	_

124-1	22285-22291	Within	_
124-2	22292-22295	the	_
124-3	22296-22305	composite	_
124-4	22306-22310	mask	_
124-5	22311-22312	,	_
124-6	22313-22324	statistical	_
124-7	22325-22329	maps	_
124-8	22330-22334	were	_
124-9	22335-22346	thresholded	_
124-10	22347-22357	correcting	_
124-11	22358-22361	for	_
124-12	22362-22373	family-wise	_
124-13	22374-22379	error	_
124-14	22380-22382	at	_
124-15	22383-22393	Pcorrected	_
124-16	22394-22395	<	_
124-17	22396-22400	0.05	_
124-18	22401-22402	(	_
124-19	22403-22414	Pvoxel-wise	_
124-20	22415-22416	<	_
124-21	22417-22422	0.001	_
124-22	22423-22424	,	_
124-23	22425-22432	cluster	_
124-24	22433-22439	extent	_
124-25	22440-22441	:	_
124-26	22442-22443	9	_
124-27	22444-22450	voxels	_
124-28	22451-22452	,	_
124-29	22453-22457	7684	_
124-30	22458-22464	voxels	_
124-31	22465-22467	in	_
124-32	22468-22477	composite	_
124-33	22478-22482	mask	_
124-34	22483-22484	)	_
124-35	22485-22486	.	_

125-1	22487-22490	For	_
125-2	22491-22500	graphical	_
125-3	22501-22512	examination	_
125-4	22513-22516	and	_
125-5	22517-22526	follow-up	_
125-6	22527-22535	analyses	_
125-7	22536-22537	,	_
125-8	22538-22540	we	_
125-9	22541-22550	extracted	_
125-10	22551-22554	the	_
125-11	22555-22559	mean	_
125-12	22560-22568	contrast	_
125-13	22569-22575	values	_
125-14	22576-22577	(	_
125-15	22578-22580	iE	_
125-16	22581-22582	−	_
125-17	22583-22585	iC	_
125-18	22586-22588	βs	_
125-19	22589-22590	)	_
125-20	22591-22593	as	_
125-21	22594-22598	well	_
125-22	22599-22601	as	_
125-23	22602-22605	the	_
125-24	22606-22616	individual	_
125-25	22617-22618	β	_
125-26	22619-22631	coefficients	_
125-27	22632-22635	for	_
125-28	22636-22638	iE	_
125-29	22639-22642	and	_
125-30	22643-22645	iC	_
125-31	22646-22652	trials	_
125-32	22653-22657	from	_
125-33	22658-22663	those	_
125-34	22664-22668	ROIs	_
125-35	22669-22676	showing	_
125-36	22677-22683	smoker	_
125-37	22684-22690	versus	_
125-38	22691-22700	nonsmoker	_
125-39	22701-22712	differences	_
125-40	22713-22714	.	_

126-1	22715-22717	To	_
126-2	22718-22722	link	_
126-3	22723-22730	altered	_
126-4	22731-22736	brain	_
126-5	22737-22745	activity	_
126-6	22746-22751	among	_
126-7	22752-22759	smokers	_
126-8	22760-22764	with	_
126-9	22765-22766	a	_
126-10	22767-22777	clinically	_
126-11	22778-22786	relevant	_
126-12	22787-22796	construct	_
126-13	22797-22798	,	_
126-14	22799-22801	we	_
126-15	22802-22811	conducted	_
126-16	22812-22813	a	_
126-17	22814-22820	priori	_
126-18	22821-22833	hypothesized	_
126-19	22834-22841	Pearson	_
126-20	22842-22843	’	_
126-21	22844-22845	s	_
126-22	22846-22858	correlations	_
126-23	22859-22866	between	_
126-24	22867-22870	the	_
126-25	22871-22872	[	_
126-26	22873-22875	iE	_
126-27	22876-22877	−	_
126-28	22878-22880	iC	_
126-29	22881-22882	]	_
126-30	22883-22891	contrast	_
126-31	22892-22898	values	_
126-32	22899-22903	from	_
126-33	22904-22914	identified	_
126-34	22915-22919	ROIs	_
126-35	22920-22923	and	_
126-36	22924-22931	smokers	_
126-37	22932-22933	’	_
126-38	22934-22938	FTND	_
126-39	22939-22945	scores	_
126-40	22946-22950	that	_
126-41	22951-22958	reflect	_
126-42	22959-22964	trait	_
126-43	22965-22971	levels	_
126-44	22972-22974	of	_
126-45	22975-22984	addiction	_
126-46	22985-22993	severity	_
126-47	22994-22995	.	_

127-1	22996-22999	The	_
127-2	23000-23001	P	_
127-3	23002-23008	values	_
127-4	23009-23018	resulting	_
127-5	23019-23023	from	_
127-6	23024-23029	these	_
127-7	23030-23031	a	_
127-8	23032-23038	priori	_
127-9	23039-23050	correlation	_
127-10	23051-23059	analyses	_
127-11	23060-23064	were	_
127-12	23065-23086	Bonferronni-corrected	_
127-13	23087-23088	(	_
127-14	23089-23090	n	_
127-15	23091-23092	=	_
127-16	23093-23094	3	_
127-17	23095-23096	;	_
127-18	23097-23100	the	_
127-19	23101-23107	number	_
127-20	23108-23110	of	_
127-21	23111-23115	ROIs	_
127-22	23116-23126	considered	_
127-23	23127-23128	)	_
127-24	23129-23130	.	_

128-1	23131-23133	To	_
128-2	23134-23141	further	_
128-3	23142-23146	link	_
128-4	23147-23163	feedback-related	_
128-5	23164-23169	brain	_
128-6	23170-23178	activity	_
128-7	23179-23183	from	_
128-8	23184-23187	all	_
128-9	23188-23200	participants	_
128-10	23201-23205	with	_
128-11	23206-23219	self-reported	_
128-12	23220-23226	affect	_
128-13	23227-23228	,	_
128-14	23229-23231	we	_
128-15	23232-23241	conducted	_
128-16	23242-23246	post	_
128-17	23247-23250	hoc	_
128-18	23251-23262	exploratory	_
128-19	23263-23275	correlations	_
128-20	23276-23283	between	_
128-21	23284-23285	[	_
128-22	23286-23288	iE	_
128-23	23289-23290	−	_
128-24	23291-23293	iC	_
128-25	23294-23295	]	_
128-26	23296-23304	contrast	_
128-27	23305-23311	values	_
128-28	23312-23315	and	_
128-29	23316-23320	each	_
128-30	23321-23332	participant	_
128-31	23333-23334	’	_
128-32	23335-23336	s	_
128-33	23337-23342	PANAS	_
128-34	23343-23349	scores	_
128-35	23350-23351	.	_

129-1	23352-23357	Given	_
129-2	23358-23362	that	_
129-3	23363-23365	we	_
129-4	23366-23370	were	_
129-5	23371-23381	interested	_
129-6	23382-23384	in	_
129-7	23385-23390	trait	_
129-8	23391-23397	levels	_
129-9	23398-23400	of	_
129-10	23401-23407	affect	_
129-11	23408-23409	(	_
129-12	23410-23421	paralleling	_
129-13	23422-23425	the	_
129-14	23426-23442	session-averaged	_
129-15	23443-23444	,	_
129-16	23445-23456	trait-level	_
129-17	23457-23467	assessment	_
129-18	23468-23470	of	_
129-19	23471-23476	brain	_
129-20	23477-23485	activity	_
129-21	23486-23487	)	_
129-22	23488-23489	,	_
129-23	23490-23492	we	_
129-24	23493-23501	computed	_
129-25	23502-23503	a	_
129-26	23504-23520	session-averaged	_
129-27	23521-23527	metric	_
129-28	23528-23530	of	_
129-29	23531-23539	positive	_
129-30	23540-23543	and	_
129-31	23544-23552	negative	_
129-32	23553-23559	affect	_
129-33	23560-23561	.	_

130-1	23562-23574	Specifically	_
130-2	23575-23576	,	_
130-3	23577-23589	participants	_
130-4	23590-23599	completed	_
130-5	23600-23603	the	_
130-6	23604-23609	PANAS	http://maven.renci.org/NeuroBridge/neurobridge#Analyzer
130-7	23610-23612	at	_
130-8	23613-23617	each	_
130-9	23618-23623	study	_
130-10	23624-23629	visit	_
130-11	23630-23631	,	_
130-12	23632-23635	and	_
130-13	23636-23638	we	_
130-14	23639-23643	were	_
130-15	23644-23654	interested	_
130-16	23655-23657	in	_
130-17	23658-23660	an	_
130-18	23661-23671	individual	_
130-19	23672-23673	’	_
130-20	23674-23675	s	_
130-21	23676-23683	general	_
130-22	23684-23689	level	_
130-23	23690-23692	of	_
130-24	23693-23699	affect	_
130-25	23700-23702	as	_
130-26	23703-23710	opposed	_
130-27	23711-23713	to	_
130-28	23714-23732	session-to-session	_
130-29	23733-23745	fluctuations	_
130-30	23746-23747	.	_

131-1	23748-23753	These	_
131-2	23754-23765	exploratory	_
131-3	23766-23777	correlation	_
131-4	23778-23786	analyses	_
131-5	23787-23791	were	_
131-6	23792-23795	not	_
131-7	23796-23817	Bonferronni-corrected	_
131-8	23818-23821	for	_
131-9	23822-23830	multiple	_
131-10	23831-23842	comparisons	_
131-11	23843-23844	.	_

132-1	23845-23849	Drug	_
132-2	23850-23857	effects	_
132-3	23858-23860	To	_
132-4	23861-23870	delineate	_
132-5	23871-23881	functional	_
132-6	23882-23893	alterations	_
132-7	23894-23900	linked	_
132-8	23901-23905	with	_
132-9	23906-23911	acute	_
132-10	23912-23916	drug	_
132-11	23917-23931	administration	_
132-12	23932-23933	,	_
132-13	23934-23936	we	_
132-14	23937-23945	assessed	_
132-15	23946-23947	β	_
132-16	23948-23959	coefficient	_
132-17	23960-23966	images	_
132-18	23967-23971	from	_
132-19	23972-23974	iC	_
132-20	23975-23976	(	_
132-21	23977-23985	positive	_
132-22	23986-23987	)	_
132-23	23988-23996	feedback	_
132-24	23997-24003	trials	_
132-25	24004-24006	in	_
132-26	24007-24008	a	_
132-27	24009-24012	LME	_
132-28	24013-24022	framework	_
132-29	24023-24024	(	_
132-30	24025-24030	3dLME	_
132-31	24031-24032	,	_
132-32	24033-24039	v1.9.8	_
132-33	24040-24041	)	_
132-34	24042-24043	,	_
132-35	24044-24053	including	_
132-36	24054-24061	factors	_
132-37	24062-24065	for	_
132-38	24066-24071	GROUP	_
132-39	24072-24073	(	_
132-40	24074-24081	between	_
132-41	24082-24094	participants	_
132-42	24095-24096	:	_
132-43	24097-24103	smoker	_
132-44	24104-24110	versus	_
132-45	24111-24120	nonsmoker	_
132-46	24121-24122	)	_
132-47	24123-24124	,	_
132-48	24125-24130	PATCH	_
132-49	24131-24132	(	_
132-50	24133-24139	within	_
132-51	24140-24152	participants	_
132-52	24153-24154	:	_
132-53	24155-24163	nicotine	_
132-54	24164-24170	versus	_
132-55	24171-24178	placebo	_
132-56	24179-24180	)	_
132-57	24181-24182	,	_
132-58	24183-24186	and	_
132-59	24187-24191	PILL	_
132-60	24192-24193	(	_
132-61	24194-24200	within	_
132-62	24201-24213	participants	_
132-63	24214-24215	:	_
132-64	24216-24224	pre-pill	_
132-65	24225-24226	,	_
132-66	24227-24238	varenicline	_
132-67	24239-24240	,	_
132-68	24241-24247	versus	_
132-69	24248-24255	placebo	_
132-70	24256-24257	)	_
132-71	24258-24259	.	_

133-1	24260-24263	The	_
133-2	24264-24267	LME	_
133-3	24268-24277	framework	_
133-4	24278-24281	was	_
133-5	24282-24286	used	_
133-6	24287-24292	given	_
133-7	24293-24300	missing	_
133-8	24301-24308	session	_
133-9	24309-24313	data	_
133-10	24314-24324	associated	_
133-11	24325-24329	with	_
133-12	24330-24333	our	_
133-13	24334-24340	motion	_
133-14	24341-24350	censoring	_
133-15	24351-24359	criteria	_
133-16	24360-24369	described	_
133-17	24370-24375	above	_
133-18	24376-24377	.	_

134-1	24378-24380	We	_
134-2	24381-24388	focused	_
134-3	24389-24391	on	_
134-4	24392-24394	iC	_
134-5	24395-24403	feedback	_
134-6	24404-24410	trials	_
134-7	24411-24416	given	_
134-8	24417-24421	that	_
134-9	24422-24423	a	_
134-10	24424-24430	larger	_
134-11	24431-24437	effect	_
134-12	24438-24442	size	_
134-13	24443-24446	was	_
134-14	24447-24455	observed	_
134-15	24456-24459	for	_
134-16	24460-24465	these	_
134-17	24466-24472	trials	_
134-18	24473-24474	(	_
134-19	24475-24483	relative	_
134-20	24484-24486	to	_
134-21	24487-24489	iE	_
134-22	24490-24498	feedback	_
134-23	24499-24500	)	_
134-24	24501-24505	when	_
134-25	24506-24515	assessing	_
134-26	24516-24522	smoker	_
134-27	24523-24529	versus	_
134-28	24530-24539	nonsmoker	_
134-29	24540-24551	differences	_
134-30	24552-24554	in	_
134-31	24555-24558	the	_
134-32	24559-24564	group	_
134-33	24565-24572	effects	_
134-34	24573-24581	analysis	_
134-35	24582-24587	above	_
134-36	24588-24589	.	_

135-1	24590-24601	Significant	_
135-2	24602-24613	interaction	_
135-3	24614-24621	effects	_
135-4	24622-24631	involving	_
135-5	24632-24635	the	_
135-6	24636-24641	GROUP	_
135-7	24642-24648	factor	_
135-8	24649-24655	and/or	_
135-9	24656-24661	PATCH	_
135-10	24662-24666	main	_
135-11	24667-24674	effects	_
135-12	24675-24679	were	_
135-13	24680-24688	followed	_
135-14	24689-24691	by	_
135-15	24692-24704	within-group	_
135-16	24705-24706	(	_
135-17	24707-24711	i.e.	_
135-18	24712-24713	,	_
135-19	24714-24721	smokers	_
135-20	24722-24723	)	_
135-21	24724-24727	LME	_
135-22	24728-24736	analyses	_
135-23	24737-24746	including	_
135-24	24747-24752	PATCH	_
135-25	24753-24756	and	_
135-26	24757-24761	PILL	_
135-27	24762-24764	as	_
135-28	24765-24772	factors	_
135-29	24773-24774	.	_

136-1	24775-24779	Main	_
136-2	24780-24783	and	_
136-3	24784-24795	interaction	_
136-4	24796-24803	effects	_
136-5	24804-24808	were	_
136-6	24809-24811	of	_
136-7	24812-24820	interest	_
136-8	24821-24822	.	_

137-1	24823-24829	Within	_
137-2	24830-24834	this	_
137-3	24835-24843	analysis	_
137-4	24844-24849	model	_
137-5	24850-24851	,	_
137-6	24852-24853	a	_
137-7	24854-24861	general	_
137-8	24862-24868	linear	_
137-9	24869-24870	t	_
137-10	24871-24875	test	_
137-11	24876-24879	was	_
137-12	24880-24889	performed	_
137-13	24890-24899	comparing	_
137-14	24900-24908	nicotine	_
137-15	24909-24915	versus	_
137-16	24916-24923	placebo	_
137-17	24924-24929	patch	_
137-18	24930-24932	to	_
137-19	24933-24941	visually	_
137-20	24942-24951	represent	_
137-21	24952-24955	the	_
137-22	24956-24965	direction	_
137-23	24966-24968	of	_
137-24	24969-24981	drug-related	_
137-25	24982-24993	alterations	_
137-26	24994-24995	(	_
137-27	24996-25000	i.e.	_
137-28	25001-25002	,	_
137-29	25003-25011	nicotine	_
137-30	25012-25013	<	_
137-31	25014-25021	placebo	_
137-32	25022-25023	,	_
137-33	25024-25032	nicotine	_
137-34	25033-25034	>	_
137-35	25035-25042	placebo	_
137-36	25043-25044	)	_
137-37	25045-25055	associated	_
137-38	25056-25060	with	_
137-39	25061-25064	the	_
137-40	25065-25070	PATCH	_
137-41	25071-25075	main	_
137-42	25076-25082	effect	_
137-43	25083-25084	.	_

138-1	25085-25087	To	_
138-2	25088-25096	maximize	_
138-3	25097-25100	the	_
138-4	25101-25110	potential	_
138-5	25111-25114	for	_
138-6	25115-25124	producing	_
138-7	25125-25138	generalizable	_
138-8	25139-25146	results	_
138-9	25147-25150	and	_
138-10	25151-25161	minimizing	_
138-11	25162-25166	type	_
138-12	25167-25168	I	_
138-13	25169-25174	error	_
138-14	25175-25180	rates	_
138-15	25181-25182	,	_
138-16	25183-25187	this	_
138-17	25188-25191	LME	_
138-18	25192-25197	model	_
138-19	25198-25202	used	_
138-20	25203-25204	a	_
138-21	25205-25206	“	_
138-22	25207-25214	maximal	_
138-23	25215-25221	random	_
138-24	25222-25229	effects	_
138-25	25230-25239	structure	_
138-26	25240-25241	”	_
138-27	25242-25243	(	_
138-28	25244-25248	i.e.	_
138-29	25249-25250	,	_
138-30	25251-25259	included	_
138-31	25260-25266	random	_
138-32	25267-25277	intercepts	_
138-33	25278-25281	for	_
138-34	25282-25294	participants	_
138-35	25295-25298	and	_
138-36	25299-25305	random	_
138-37	25306-25312	slopes	_
138-38	25313-25316	for	_
138-39	25317-25320	the	_
138-40	25321-25326	PATCH	_
138-41	25327-25328	,	_
138-42	25329-25333	PILL	_
138-43	25334-25335	,	_
138-44	25336-25339	and	_
138-45	25340-25345	PATCH	_
138-46	25346-25347	*	_
138-47	25348-25352	PILL	_
138-48	25353-25360	effects	_
138-49	25361-25362	;	_
138-50	25363-25370	-ranEff	_
138-51	25371-25372	‘	_
138-52	25373-25375	~1	_
138-53	25376-25377	+	_
138-54	25378-25383	patch	_
138-55	25384-25385	+	_
138-56	25386-25390	pill	_
138-57	25391-25392	+	_
138-58	25393-25397	pill	_
138-59	25398-25399	*	_
138-60	25400-25405	patch	_
138-61	25406-25407	’	_
138-62	25408-25409	)	_
138-63	25410-25411	.	_

139-1	25412-25423	Statistical	_
139-2	25424-25428	maps	_
139-3	25429-25433	were	_
139-4	25434-25445	thresholded	_
139-5	25446-25456	correcting	_
139-6	25457-25460	for	_
139-7	25461-25472	family-wise	_
139-8	25473-25478	error	_
139-9	25479-25485	within	_
139-10	25486-25489	the	_
139-11	25490-25499	composite	_
139-12	25500-25504	mask	_
139-13	25505-25507	as	_
139-14	25508-25517	described	_
139-15	25518-25523	above	_
139-16	25524-25527	for	_
139-17	25528-25531	the	_
139-18	25532-25537	group	_
139-19	25538-25545	effects	_
139-20	25546-25554	analysis	_
139-21	25555-25556	.	_

140-1	25557-25559	We	_
140-2	25560-25569	extracted	_
140-3	25570-25573	the	_
140-4	25574-25575	β	_
140-5	25576-25588	coefficients	_
140-6	25589-25593	from	_
140-7	25594-25598	both	_
140-8	25599-25602	the	_
140-9	25603-25605	iC	_
140-10	25606-25609	and	_
140-11	25610-25612	iE	_
140-12	25613-25619	trials	_
140-13	25620-25624	from	_
140-14	25625-25630	those	_
140-15	25631-25635	ROIs	_
140-16	25636-25646	separately	_
140-17	25647-25654	showing	_
140-18	25655-25667	drug-induced	_
140-19	25668-25675	effects	_
140-20	25676-25679	for	_
140-21	25680-25683	all	_
140-22	25684-25687	six	_
140-23	25688-25692	drug	_
140-24	25693-25703	conditions	_
140-25	25704-25707	and	_
140-26	25708-25714	across	_
140-27	25715-25719	both	_
140-28	25720-25726	groups	_
140-29	25727-25728	(	_
140-30	25729-25736	smokers	_
140-31	25737-25740	and	_
140-32	25741-25751	nonsmokers	_
140-33	25752-25753	)	_
140-34	25754-25757	for	_
140-35	25758-25769	qualitative	_
140-36	25770-25779	graphical	_
140-37	25780-25781	[	_
140-38	25782-25784	to	_
140-39	25785-25790	avoid	_
140-40	25791-25792	a	_
140-41	25793-25801	circular	_
140-42	25802-25810	analysis	_
140-43	25811-25812	]	_
140-44	25813-25819	and/or	_
140-45	25820-25829	selective	_
140-46	25830-25842	quantitative	_
140-47	25843-25854	statistical	_
140-48	25855-25866	examination	_
140-49	25867-25868	,	_
140-50	25869-25876	thereby	_
140-51	25877-25889	facilitating	_
140-52	25890-25903	comprehensive	_
140-53	25904-25918	interpretation	_
140-54	25919-25921	of	_
140-55	25922-25937	pharmacological	_
140-56	25938-25945	effects	_
140-57	25946-25947	.	_

141-1	25948-25953	While	_
141-2	25954-25955	a	_
141-3	25956-25965	selective	_
141-4	25966-25974	analysis	_
141-5	25975-25977	of	_
141-6	25978-25985	smokers	_
141-7	25986-25987	’	_
141-8	25988-25990	iC	_
141-9	25991-25992	β	_
141-10	25993-26005	coefficients	_
141-11	26006-26011	would	_
141-12	26012-26023	constituent	_
141-13	26024-26025	a	_
141-14	26026-26034	circular	_
141-15	26035-26043	analysis	_
141-16	26044-26045	,	_
141-17	26046-26048	we	_
141-18	26049-26058	extracted	_
141-19	26059-26064	these	_
141-20	26065-26074	parameter	_
141-21	26075-26084	estimates	_
141-22	26085-26089	only	_
141-23	26090-26093	for	_
141-24	26094-26103	graphical	_
141-25	26104-26118	representation	_
141-26	26119-26120	.	_

142-1	26121-26126	Given	_
142-2	26127-26131	that	_
142-3	26132-26135	the	_
142-4	26136-26138	iE	_
142-5	26139-26140	β	_
142-6	26141-26153	coefficients	_
142-7	26154-26158	were	_
142-8	26159-26168	unrelated	_
142-9	26169-26171	to	_
142-10	26172-26175	the	_
142-11	26176-26187	statistical	_
142-12	26188-26192	test	_
142-13	26193-26197	used	_
142-14	26198-26200	to	_
142-15	26201-26209	identify	_
142-16	26210-26216	voxels	_
142-17	26217-26219	of	_
142-18	26220-26228	interest	_
142-19	26229-26230	,	_
142-20	26231-26233	we	_
142-21	26234-26242	assessed	_
142-22	26243-26252	parameter	_
142-23	26253-26262	estimates	_
142-24	26263-26267	from	_
142-25	26268-26274	select	_
142-26	26275-26282	regions	_
142-27	26283-26285	in	_
142-28	26286-26287	a	_
142-29	26288-26293	GROUP	_
142-30	26294-26295	*	_
142-31	26296-26301	PATCH	_
142-32	26302-26303	*	_
142-33	26304-26308	PILL	_
142-34	26309-26322	mixed-effects	_
142-35	26323-26328	ANOVA	_
142-36	26329-26334	using	_
142-37	26335-26339	SPSS	_
142-38	26340-26341	.	_

143-1	26342-26353	Significant	_
143-2	26354-26366	interactions	_
143-3	26367-26376	involving	_
143-4	26377-26380	the	_
143-5	26381-26386	GROUP	_
143-6	26387-26393	factor	_
143-7	26394-26400	and/or	_
143-8	26401-26406	PATCH	_
143-9	26407-26411	main	_
143-10	26412-26419	effects	_
143-11	26420-26424	were	_
143-12	26425-26433	followed	_
143-13	26434-26436	by	_
143-14	26437-26449	within-group	_
143-15	26450-26451	,	_
143-16	26452-26469	repeated-measures	_
143-17	26470-26476	ANOVAs	_
143-18	26477-26486	including	_
143-19	26487-26492	PATCH	_
143-20	26493-26496	and	_
143-21	26497-26501	PILL	_
143-22	26502-26504	as	_
143-23	26505-26512	factors	_
143-24	26513-26514	.	_

144-1	26515-26517	To	_
144-2	26518-26522	link	_
144-3	26523-26541	session-to-session	_
144-4	26542-26554	fluctuations	_
144-5	26555-26557	in	_
144-6	26558-26563	brain	_
144-7	26564-26572	activity	_
144-8	26573-26578	among	_
144-9	26579-26586	smokers	_
144-10	26587-26591	with	_
144-11	26592-26593	a	_
144-12	26594-26604	clinically	_
144-13	26605-26613	relevant	_
144-14	26614-26623	construct	_
144-15	26624-26625	,	_
144-16	26626-26628	we	_
144-17	26629-26638	conducted	_
144-18	26639-26640	a	_
144-19	26641-26647	priori	_
144-20	26648-26660	hypothesized	_
144-21	26661-26667	RMcorr	_
144-22	26668-26675	between	_
144-23	26676-26692	session-specific	_
144-24	26693-26695	iC	_
144-25	26696-26697	β	_
144-26	26698-26704	values	_
144-27	26705-26709	from	_
144-28	26710-26720	identified	_
144-29	26721-26725	ROIs	_
144-30	26726-26729	and	_
144-31	26730-26737	smokers	_
144-32	26738-26739	’	_
144-33	26740-26756	session-specific	_
144-34	26757-26760	TCQ	_
144-35	26761-26767	scores	_
144-36	26768-26772	that	_
144-37	26773-26780	reflect	_
144-38	26781-26782	a	_
144-39	26783-26794	state-level	_
144-40	26795-26802	measure	_
144-41	26803-26805	of	_
144-42	26806-26816	withdrawal	_
144-43	26817-26823	status	_
144-44	26824-26825	.	_

145-1	26826-26832	RMcorr	_
145-2	26833-26835	is	_
145-3	26836-26837	a	_
145-4	26838-26849	statistical	_
145-5	26850-26859	procedure	_
145-6	26860-26871	implemented	_
145-7	26872-26874	in	_
145-8	26875-26876	R	_
145-9	26877-26878	(	_
145-10	26879-26885	v3.5.0	_
145-11	26886-26887	)	_
145-12	26888-26890	to	_
145-13	26891-26903	characterize	_
145-14	26904-26907	the	_
145-15	26908-26926	within-participant	_
145-16	26927-26938	association	_
145-17	26939-26946	between	_
145-18	26947-26950	two	_
145-19	26951-26959	measures	_
145-20	26960-26968	assessed	_
145-21	26969-26971	on	_
145-22	26972-26975	two	_
145-23	26976-26978	or	_
145-24	26979-26983	more	_
145-25	26984-26993	occasions	_
145-26	26994-27000	common	_
145-27	27001-27007	across	_
145-28	27008-27011	all	_
145-29	27012-27024	participants	_
145-30	27025-27026	.	_

146-1	27027-27030	The	_
146-2	27031-27032	P	_
146-3	27033-27039	values	_
146-4	27040-27049	resulting	_
146-5	27050-27054	from	_
146-6	27055-27060	these	_
146-7	27061-27062	a	_
146-8	27063-27069	priori	_
146-9	27070-27076	RMcorr	_
146-10	27077-27085	analyses	_
146-11	27086-27090	were	_
146-12	27091-27112	Bonferronni-corrected	_
146-13	27113-27114	(	_
146-14	27115-27116	n	_
146-15	27117-27118	=	_
146-16	27119-27120	3	_
146-17	27121-27122	;	_
146-18	27123-27126	the	_
146-19	27127-27133	number	_
146-20	27134-27136	of	_
146-21	27137-27141	ROIs	_
146-22	27142-27152	considered	_
146-23	27153-27154	)	_
146-24	27155-27156	.	_

147-1	27157-27159	To	_
147-2	27160-27167	further	_
147-3	27168-27172	link	_
147-4	27173-27191	session-to-session	_
147-5	27192-27204	fluctuations	_
147-6	27205-27207	in	_
147-7	27208-27213	brain	_
147-8	27214-27222	activity	_
147-9	27223-27227	from	_
147-10	27228-27231	all	_
147-11	27232-27244	participants	_
147-12	27245-27249	with	_
147-13	27250-27263	self-reported	_
147-14	27264-27273	anhedonia	_
147-15	27274-27275	,	_
147-16	27276-27278	we	_
147-17	27279-27288	conducted	_
147-18	27289-27293	post	_
147-19	27294-27297	hoc	_
147-20	27298-27309	exploratory	_
147-21	27310-27316	RMcorr	_
147-22	27317-27324	between	_
147-23	27325-27341	session-specific	_
147-24	27342-27344	iC	_
147-25	27345-27349	beta	_
147-26	27350-27356	values	_
147-27	27357-27360	and	_
147-28	27361-27365	each	_
147-29	27366-27377	participant	_
147-30	27378-27379	’	_
147-31	27380-27381	s	_
147-32	27382-27398	session-specific	_
147-33	27399-27403	RSAS	_
147-34	27404-27410	scores	_
147-35	27411-27412	.	_

148-1	27413-27418	These	_
148-2	27419-27430	exploratory	_
148-3	27431-27437	RMcorr	_
148-4	27438-27446	analyses	_
148-5	27447-27451	were	_
148-6	27452-27455	not	_
148-7	27456-27465	corrected	_
148-8	27466-27469	for	_
148-9	27470-27478	multiple	_
148-10	27479-27490	comparisons	_
148-11	27491-27492	.	_

